

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 229/38, A61K 31/24		A1	(11) International Publication Number: WO 99/55661
			(43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/GB99/01263 (22) International Filing Date: 23 April 1999 (23.04.99) (30) Priority Data: 9808813.1 24 April 1998 (24.04.98) GB 9822432.1 14 October 1998 (14.10.98) GB (71) Applicant (for all designated States except US): PROTEUS MOLECULAR DESIGN LIMITED [GB/GB]; Beechfield House, Lyme Green Business Park, Macclesfield, Cheshire SK11 0JL (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): WASZKOWYCZ, Bohdan [GB/GB]; Beechfield House, Lyme Green Business Park, Macclesfield, Cheshire SK11 0JL (GB). LIVELY, Sarah, Elizabeth [GB/GB]; Beechfield House, Lyme Green Business Park, Macclesfield, Cheshire SK11 0JL (GB). HARRISON, Martin, James [GB/GB]; Beechfield House, Lyme Green Business Park, Macclesfield, Cheshire SK11 0JL (GB). (74) Agents: COCKBAIN, Julian et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: AMINOMETHYL-BENZOIC ESTER DERIVATIVES AS TRYPTASE INHIBITORS			
<div style="text-align: center;"> <p>(I)</p> </div>			
(57) Abstract <p>The invention relates to the use of compounds of formula (I) wherein R represents hydrogen, alkyl, alkenyl, hydroxy, alkoxy, aminoalkyl, hydroxyalkyl, carboxyalkyl, alkoxyalkyl, amino, halo, cyano, nitro, thiol, alkylthio, haloalkoxy or haloalkyl; Ar represents an optionally substituted carbocyclic or heterocyclic aryl group with the proviso that when Ar represents a naphthyl moiety it is not substituted by amidino or guanidine; and Y represents a hydrogen atom or alkyl group; or a physiologically tolerable salt thereof; for use as tryptase inhibitors.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AMINOMETHYL-BENZOIC ESTER DERIVATIVES AS TRYPTASE INHIBITORS

The invention relates to compounds for use in the treatment of mast cell mediated diseases such as asthma and other allergic and inflammatory conditions and to pharmaceutical compositions thereof and their use in the treatment of the human or animal body, and in particular to compounds which are tryptase inhibitors.

Asthma, the most prevalent of all mast cell mediated conditions affects about 5% of the population in industrialised countries and there is evidence that its incidence and severity are on the increase. Furthermore, the incidence of childhood asthma is rising and there are suggestions of a link between environmental pollutants and the onset of the disease.

Initially, it was believed that bronchoconstriction, i.e. the narrowing of the airways in the lungs, was the major feature of asthma. However, it is now recognised that inflammation in the lungs is an integral part of the development of the disease.

The inhalation of an allergen by an asthmatic generates a strong immune system response which triggers release of various inflammatory mediators, including histamine and leukotrienes from inflammatory cells. These increase the permeability of the blood vessel walls, attract inflammatory cells into the tissues and contract the smooth muscle around the airways. As a result, fluid leaks from the blood and the tissues swell, further narrowing the airways. The inflammatory cells cause damage to the epithelial cells lining the airways exposing nerve endings which stimulates secretion of mucous as well as augmenting the inflammation by causing the release of neurokinins.

Thus asthma is a complex disease frequently characterised by progressive developments of hyper-responsiveness of the trachea and bronchi as a result of

- 2 -

chronic inflammation reactions which irritate the epithelium lining the airway and cause pathological thickening of the underlying tissues.

5 Leukocytes and mast cells are present in the epithelium and smooth muscle tissue of the bronchi where they are activated initially by binding of specific inhaled antigens to IgE receptors. Activated mast cells release a number of preformed or primary chemical mediators of the inflammatory response in asthma as well
10 as enzymes. Moreover, secondary mediators of inflammation are generated by enzymatic reactions of activated mast cells and a number of large molecules are released by degranulation of mast cells.

It has therefore been proposed that chemical
15 release from mast cells properly accounts for the early bronchiolar constriction response that occurs in susceptible individuals after exposure to airborne allergens. The early asthmatic reaction is maximal at around 15 minutes after allergen exposure, recovery
20 occurring over the ensuing 1 to 2 hours. In approximately 30% of individuals, the early asthmatic reaction is followed by a further decline in respiratory function which normally begins within a few hours and is maximal between 6 and 12 hours after exposure. This
25 late asthmatic reaction is accompanied by a marked increase in the number of inflammatory cells infiltrating bronchiolar smooth muscle and epithelial tissues, and spilling into the airways. These cells are attracted to the site by release of mast cell derived
30 chemotactic agents.

The most straightforward way of dealing with an asthma attack is with a bronchodilator drug which causes airways to expand. The most effective bronchodilators are the β -adrenergic agonists which mimic the actions of
35 adrenalin. These are widely used and are simply administered to the lungs by inhalers. However, bronchoconstrictor drugs are primarily of use in short

- 3 -

term symptomatic relief, and do not prevent asthma attacks nor deterioration of lung function over the long term.

5 Anti-inflammatory drugs such as cromoglycate and the corticosteroids are also widely used in asthma therapy. Cromoglycate has anti-inflammatory activity and has been found to be extremely safe. Although such cromolyns have minimal side effects and are currently preferred for initial preventive therapy in children, it
10 is well known that they are of limited efficacy.

The use of corticosteroids in asthma therapy was a major advance since they are very effective anti-inflammatory agents, however, steroids are very powerful, broad spectrum anti-inflammatory agents and
15 their potency and non-specificity means that they are seriously limited by adverse side effects. Localising steroid treatment to the lungs using inhaler technology has reduced side effects but the reduced systemic exposure following inhalation still results in some
20 undesirable effects. Hence, there is a reluctance to use steroids early in the course of the disease.

There therefore still remains a need for an alternative asthma therapy which is a safe, effective, anti-inflammatory or immunomodulatory agent which can be
25 taken to treat chronic asthma.

Tryptase is the major secretory protease of human mast cells and is proposed to be involved in neuropeptide processing and tissue inflammation. Tryptase is one of a large number of serine protease
30 enzymes which play a central role in the regulation of a wide variety of physiological processes including coagulation, fibrinolysis, fertilization, development, malignancy, neuromuscular patterning and inflammation. Although a large number of serine proteases have been
35 widely investigated, tryptase still remains relatively unexplored.

Mature human tryptase is a glycosylated, heparin-

associated tetramer of catalytically active subunits. Its amino-acid structure appears to have no close counterpart among the other serine proteases which have been characterised. Tryptase is stored in mast cell secretory granules and after mast cell activation, human tryptase can be measured readily in a variety of biological fluids. For example, after anaphylaxis, tryptase appears in the blood stream where it is readily detectable for several hours. Tryptase also appears in samples of nasal and lung lavage fluid from atopic subjects challenged with specific antigen.

Tryptase has been implicated in a variety of biological processes, including degradation of vaso-dilating and bronchorelaxing neuropeptides thereby destroying potent bronchodilatory action and modulation of bronchial responsiveness to histamine. Accordingly, mast cell tryptase may increase bronchoconstriction in asthma by destroying bronchodilating peptides. Moreover, the ability of tryptase to activate prostromelysin and procollagenase suggests that tryptase also may be involved in tissue inflammation. Accordingly, tryptase has been proposed as a potentially important mediator in the development of inflammatory response in asthma and other inflammatory diseases. Accordingly, tryptase inhibition may be of great value in the prophylaxis and treatment of a variety of mast cell mediated conditions, such as asthma, particularly in the treatment of chronic, late stage inflammatory asthma.

In WO96/09297, WO95/32945, WO94/20527 and US 5,525,623 a variety of peptide based compounds are suggested as potential inhibitors of the mast cell protease tryptase. In WO95/03333 a tryptase inhibitor is provided by a polypeptide obtainable from the leech *hirudo medicinalis*. In WO96/08275 secretory leukocyte protease inhibitor (SLPI) and active fragments thereof have been found to inhibit the proteolytic activity of

- 5 -

tryptase.

However, it has now been surprisingly found that certain aminomethyl-benzoic ester derivatives are particularly effective as inhibitors of tryptase and show a surprising selectivity for tryptase over other serine proteases.

Aminomethyl-benzoic ester derivatives have previously been employed in a variety of fields. In US 5,628,803 aminomethyl-benzoic ester derivatives have been used as fuel additives. In EP 0048433, FR 2500825 and 2500826 a number of aminomethyl-benzoic ester derivatives are suggested as being useful in anti-complement compositions. The compounds are also said to have strong anti-trypsin, anti-plasmin and anti-kallikrein activity. In Japanese Abstract No. 57095908. aminomethyl-benzoic ester derivatives are disclosed as potential anti-allergic compounds and in Acta. Pharm. Nord. 3(1) 31-40 (1991) water-soluble aminoalkylbenzoate esters are suggested as prodrugs. In DE 1966174 and DE 1951061 a variety of aminomethyl-benzoic ester derivatives are suggested as having antiplasmin activity. However it has now been surprisingly found that certain aminomethyl benzoic ester derivatives are effective inhibitors of tryptase whilst showing a surprising selectivity for tryptase over other serine proteases such as Factor X, thrombin and trypsin.

Moreover, certain aminomethyl-benzoic ester derivatives have a prolonged biological stability, enhancing their usefulness when administered by a systemic route, such as orally or intravenously. While ester derivatives are generally poorly stable in biological systems, leading to a very limited duration of action in a therapeutic drug, stability to chemical and enzymatic hydrolysis can be enhanced by modification of the nature of the ester and/or by addition of stabilising chemical moieties. For example, the aminomethyl-benzoic ester derivatives of the present


- 6 -

invention may be substituted by a range of polar, in particular acidic, moieties that may yield a large increase in plasma stability.

It is envisaged that the compound of the invention will be useful not only in the treatment and prophylaxis of asthma but also of other allergic and inflammatory conditions mediated by tryptase such as allergic rhinitis, skin conditions such as eczema, atopic dermatitis and urticaria, rheumtoid arthritis, conjunctivitis and inflammatory bowel disease.

Thus, viewed from one aspect the invention provides the use of a tryptase inhibitor of formula I

15



20

wherein R represents hydrogen, alkyl, alkenyl, hydroxy, alkoxy, aminoalkyl, hydroxyalkyl, carboxyalkyl, alkoxyalkyl, amino, halo, cyano, nitro, thiol, alkylthio, haloalkoxy or haloalkyl;

25

Ar represents an optionally substituted carbocyclic or heterocyclic aryl group with the proviso that when Ar represents a naphthyl moiety it is not substituted by amidino or guanidine; and

30

Y represents a hydrogen atom or alkyl group; or a physiologically tolerable salt thereof, e.g. a halide, phosphate, sulphate, or trifluoroacetate salt or salt with ammonium or an organic amine such as ethylamine or meglumine;

35

in the manufacture of a medicament for use in a method of treatment of the human or non-human animal body to combat a condition responsive to said inhibitor.

In the compounds of the invention unless otherwise stated, carbocyclic aryl groups preferably contain 5 to

- 7 -

10, more especially 5 or 6 ring atoms. Heterocyclic aryl groups preferably contain 5 to 10 ring atoms including 1, 2 or 3 ring heteroatoms selected from oxygen, nitrogen and sulphur. Alkyl or alkenyl groups
 5 preferably contain up to 10 carbon atoms, most preferably, up to 6 carbon atoms.

The substituent R is preferably a short chain alkyl, e.g. C₁₋₃ alkyl such as methyl but most preferably R represents hydrogen.

10 The substituent Y is preferably a short chain alkyl, e.g. C₁₋₃ alkyl such as methyl but most preferably Y represents hydrogen.

Representative Ar groups include optionally substituted phenyl, optionally substituted naphthyl,
 15 optionally substituted pyridyl, optionally substituted quinolyl, and optionally substituted isoquinolyl. These groups should preferably carry at least one polar, especially acidic or protected acidic substituent.

In a preferred embodiment, the substituent on the
 20 carbocyclic or heterocyclic aryl group should not be strongly basic, i.e. ArH must be less basic than benzylamine. This ensures that the compounds of the invention bind more efficiently in the tryptase active site, thus maintaining selectivity.

25 Where Ar represents a phenyl derivative, the phenyl may be substituted by one or more substituents selected from: halo, for example fluoro, chloro, bromo or iodo, methylenedioxy, -R¹, -NR¹COR², C₂₋₆-alkenyl, -(CH₂)_w-OR¹,
 - (C₁₋₆)-perfluoroalkyl, -(CH₂)_wCN, -(CH₂)_wNO₂, -(CH₂)_wCF₃,
 30 -(CH₂)_wS(O)_rR¹, -(CH₂)_wNR¹R², -(CH₂)_wCOR¹, -(CH₂)_wCO₂R¹,
 -(CH₂)_wCONR¹R², -(CH₂)_wSO₂NR¹R², -(CH₂)_wNHSO₂R¹, -(CH₂)_wNHCOR¹,
 -(CH₂)_wNHCO₂R¹, -OC(=O)R¹, -(CH₂)_w-CH(NHCOR¹)-COOR², -(CH₂)_w-
 CH(NR¹R²)-COOR¹, -(CH₂)_w-CONH-SO₂-R¹, -(CH₂)_w-SO₂-NHCO-R¹, -
 (CH₂)_w-tetrazole, -(CH₂)_w-P(O)₂₋₃-R¹, -(CH₂)_w-C(=O)-R³ and
 35 optionally substituted aryl where R¹ and R² independently represent H, C₁₋₈ alkyl, C₃₋₇ cycloalkyl, or -(CH₂)_w-Ph, or R¹ and R² are optionally connected by a bond to form a 5-

- 8 -

8 atom cyclic structure (eg. piperidine) or connected via an O, S or N atom to form a 5-8 atom heterocyclic structure (eg. morpholine, piperazine) and where R¹ and/or R² are also optionally substituted with - (CH₂)_w-COOR¹, - (CH₂)_w-CH(NHCOR¹)-COOR², - (CH₂)_w-CH(NR¹R²)-COOR¹, - (CH₂)_w-CONH-SO₂-R¹, - (CH₂)_w-SO₂-NHCO-R¹, - (CH₂)_w-tetrazole, - (CH₂)_w-S(O)_r-R¹, or - (CH₂)_w-P(O)₂₋₃-R¹; R³ is an oligomer comprising 1-4 aminoacid monomers, such as the natural aminoacids glycine, proline and serine, terminated by a free carboxylic acid, ester or amide functionality; and w=0-5 and r=0-2.

Preferably the substituent will comprise an electron withdrawing group and/or at least one polar moiety, most preferably an acidic or a protected form of an acidic moiety. Preferred electron withdrawing groups include cyano, nitro, carboxamido, alkylsulfenyl, alkylsulfonyl, alkylaminosulfonyl, sulphonylaminoalkyl, trifluoromethyl, or halogen, and most preferably where the substituent is an electron withdrawing group the substituent will be on the 2 or 4-position of the phenyl group.

The presence of at least one polar moiety, most preferably an acidic or a protected form of an acidic moiety (e.g. an ester) provides enhanced biological stability. Preferred acidic groups include alkyl or aryl carboxylic acids and esters, acyl sulphonamide, sulphonylamidocarboxyalkyl, carboxyamidosulphonylalkyl, tetrazole, sulphonic acid or phosphonic acid each bonded to the Ar ring directly or via an alkyl, sulphonamidoalkyl or carboxamidoalkyl linkage, the linkage itself being optionally substituted by small polar or apolar groups such as C₁₋₄ alkyl, NH₂, CN, NO₂, NHCO-alkyl, or halogen. The acidic substituent will preferably be on the para position of the phenyl ring.

In another preferred embodiment an acidic substituent is present on the ortho position of the phenyl ring and a electron withdrawing substituent is


- 9 -

present on the para position.


Where Ar represents a naphthyl derivative, the naphthyl may be substituted by one or more substituents selected from the same group as those as listed for phenyl above. Most preferred substituents are cyano, nitro, carboxamido, alkylaminosulfonyl, alkylsulfonyl, alkylsulphenyl, sulphonylaminoalkyl or trifluoromethyl or as for phenyl above naphthyl may be substituted by at least one polar moiety, most preferably an acidic or a protected form of an acidic moiety, such as alkyl or aryl carboxylic acids and esters, acyl sulphonamide, sulphonylamidocarboxyalkyl, carboxyamidosulphonylalkyl, tetrazole, sulphonic acid or phosphonic acid each bonded to the Ar ring directly or via an alkyl, sulphonamidoalkyl or carboxamidoalkyl linkage, the linkage itself being optionally substituted by small polar or apolar groups such as C₁₋₄ alkyl, CN, NO₂, NH₂, NHCO-alkyl, or halogen.


Representative aromatic heterocyclic groups include pyridyl, quinolyl, isoquinolyl, imidazolyl, indolyl, pyrazolyl, pyrrolidinyl, imidazolidinyl, isoindolyl, pyrazolidinyl, furyl, pyrrolyl, pyrazinyl, benzothienyl, thienyl and benzofuryl. Particularly preferred heterocyclic groups are quinolyl, especially, 6-quinolyl and pyridyl, especially 3-pyridyl.

Optional substituents described above for one type of aryl Ar group may be present on the other types of aryl Ar groups. Suitable Ar groups therefore include (for convenience hydrogen atoms have been missed out):



30






- 12 -

Where the compound of formula (I) is a salt, the salt is preferably a hydrochloride or other physiologically tolerated salt.

Viewed from another aspect the invention provides
 5 novel tryptase inhibitors of formula (II)



10

wherein R and Y are as hereinbefore defined; and
 Z represents a phenyl group substituted by
 methylenedioxy, $-NR^1COR^2$, C_{2-6} -alkenyl, $-(CH_2)_w-OR^1$,
 15 $-(C_{1-6})$ -perfluoroalkyl, $-(CH_2)_wCN$, $-(CH_2)_wNO_2$, $-(CH_2)_wCF_3$, $-(CH_2)_wS(O)_rR^1$, $-(CH_2)_wNR^1R^2$, $-(CH_2)_wCOR^1$, $-(CH_2)_wCONR^1R^2$,
 $-(CH_2)_wSO_2NR^1R^2$, $-(CH_2)_wNHSO_2R^1$, $-(CH_2)_wNHCOR^1$, $-(CH_2)_wNHCO_2R^1$,
 $-OC(=O)R^1$, $-(CH_2)_w-CH(NHCOR^1)-COOR^2$, $-(CH_2)_w-CH(NR^1R^2)-COOR^1$, $-(CH_2)_w-CONH-SO_2-R^1$, $-(CH_2)_w-SO_2-NHCO-R^1$, $-(CH_2)_w-$
 20 tetrazole, $-(CH_2)_w-P(O)_{2-3}-R^1$, $-(CH_2)_w-C(=O)-R^3$ and
 optionally substituted aryl where R^1 and R^2 independently
 represent H, C_{1-8} alkyl, C_{3-7} cycloalkyl, or $-(CH_2)_w-Ph$, or
 R^1 and R^2 are optionally connected by a bond to form a 5-
 8 atom cyclic structure (eg. piperidine) or connected
 25 via an O, S or N atom to form a 5-8 atom heterocyclic
 structure (eg. morpholine, piperazine) and where R^1
 and/or R^2 are also optionally substituted with $-(CH_2)_w-$
 $COOR^1$, $-(CH_2)_w-CH(NHCOR^1)-COOR^2$, $-(CH_2)_w-CH(NR^1R^2)-COOR^1$, $-(CH_2)_w-CONH-SO_2-R^1$, $-(CH_2)_w-SO_2-NHCO-R^1$, $-(CH_2)_w-$
 30 tetrazole, $-(CH_2)_w-S(O)_r-R^1$, or $-(CH_2)_w-P(O)_{2-3}-R^1$; where R^3 is an
 oligomer comprising 1-4 aminoacid monomers, such as the
 natural aminoacids glycine, proline and serine,
 terminated by a free carboxylic acid, ester or amide
 functionality; and $w=0-5$ and $r=0-2$; or

35 Z represents a phenyl group substituted in the 2-
 position by nitro or in the 3-position by methoxy; or
 Z represents a naphthyl group substituted by halo,

for example fluoro, chloro, bromo or iodo,
 methylenedioxy, $-R^1$, $-NR^1COR^2$, C_{2-6} -alkenyl, $-(CH_2)_w-OR^1$,
 $-(C_{1-6})$ -perfluoroalkyl, $-(CH_2)_wCN$, $-(CH_2)_wNO_2$, $-(CH_2)_wCF_3$,
 $-(CH_2)_wS(O)_rR^1$, $-(CH_2)_wNR^1R^2$, $-(CH_2)_wCOR^1$, $-(CH_2)_wCO_2R^1$,
 5 $-(CH_2)_wCONR^1R^2$, $-(CH_2)_wSO_2NR^1R^2$, $-(CH_2)_wNHSO_2R^1$, $-(CH_2)_wNHCOR^1$,
 $-(CH_2)_wNHCO_2R^1$, $-OC(=O)R^1$, $-(CH_2)_w-CH(NHCOR^1)-COOR^2$, $-(CH_2)_w-$
 $CH(NR^1R^2)-COOR^1$, $-(CH_2)_w-CONH-SO_2-R^1$, $-(CH_2)_w-SO_2-NHCO-R^1$, $-$
 $(CH_2)_w$ -tetrazole, $-(CH_2)_w-P(O)_{2-3}-R^1$, $-(CH_2)_w-C(=O)-R^3$ and
 optionally substituted aryl where R^1 and R^2 independently
 10 represent H, C_{1-8} alkyl, C_{3-7} cycloalkyl, or $-(CH_2)_w-Ph$, or
 R^1 and R^2 are optionally connected by a bond to form a 5-
 8 atom cyclic structure (eg. piperidine) or connected
 via an O, S or N atom to form a 5-8 atom heterocyclic
 structure (eg. morpholine, piperazine) and where R^1
 15 and/or R^2 are also optionally substituted with $-(CH_2)_w-$
 $COOR^1$, $-(CH_2)_w-CH(NHCOR^1)-COOR^2$, $-(CH_2)_w-CH(NR^1R^2)-COOR^1$, $-$
 $(CH_2)_w-CONH-SO_2-R^1$, $-(CH_2)_w-SO_2-NHCO-R^1$, $-(CH_2)_w$ -tetrazole,
 $-(CH_2)_w-S(O)_r-R^1$, or $-(CH_2)_w-P(O)_{2-3}-R^1$; where R^3 is an
 oligomer comprising 1-4 aminoacid monomers, such as the
 20 natural aminoacids glycine, proline and serine,
 terminated by a free carboxylic acid, ester or amide
 functionality; and $w=0-5$ and $r=0-2$; or

a heterocyclic aryl groups containing 5 to 10 ring
 atoms including 1, 2 or 3 ring heteroatoms selected from
 25 oxygen, nitrogen and sulphur; or

a physiologically tolerable salt thereof.

In a preferred embodiment, ZH should be less basic
 than benzylamine. This ensures that the compounds of
 the invention bind more efficiently in the tryptase
 30 active site.

In the compounds of formula (II), R is preferably a
 short chain alkyl, e.g. C_{1-3} alkyl such as methyl but
 most preferably R represents hydrogen. Y is preferably
 a short chain alkyl, e.g. C_{1-3} alkyl such as methyl but
 35 most preferably Y represents hydrogen and wherever
 possible Z represents a preferred substituent Ar as
 defined above.

- 14 -

Viewed from a further aspect the invention provides a tryptase inhibitor of formula (II) for use in combatting a condition responsive to said inhibitor.

5 Viewed from a yet further aspect the invention provides a pharmaceutical composition comprising a compound of formula (II), together with at least one pharmaceutically acceptable excipient.

10 The compounds of the invention may be prepared by conventional chemical synthetic routes, e.g. by ester bond formation to couple the Ar-OH compound to the aminomethylbenzoic acid derivative.

15 The readily available starting material 4-aminomethyl-benzoic acid can be utilised. Prior to esterification the amino group should be protected by any appropriate protecting group e.g. Boc, Z, Fmoc or Bpoc. The use of protecting groups is described in McOmie, "Protective Groups in Organic Chemistry", Plenum, 1973 and Greene, "Protective Groups in Organic Synthesis", Wiley Interscience, 1981. The protected
20 aminomethyl-benzoic acid can be simply coupled to a suitable Ar-OH derivative by conventional esterification techniques before deprotection is effected.

25 If necessary the protected aminomethyl-benzoic acid derivative can be activated by conversion to its corresponding anhydride or acyl chloride, using conventional reagents, to facilitate esterification. If the aminomethyl-benzoic acid compound is to carry phenyl substituents these can be conveniently introduced prior to the esterification or protection step using
30 conventional aromatic substitution chemistry.

Alternatively, a starting material could be employed which already carries the substituent R and the aminomethyl functionality introduced for example by reduction of a cyano group. The Ar-OH alcohols are all
35 readily available or prepared by the skilled chemist.

The compounds of the invention may be administered by any conventional route e.g. into the gastrointestinal

- 15 -

tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature or transdermally. However, it is preferred that the compounds be administered by inhalation, orally, intravenously or topically to the skin or to the eye. The compounds may be administered in any convenient administrative form e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents and further active agents. Preferably, the composition will be suitable for inhalation via a nebulizer or inhalable spray, e.g. a metered dose inhaler or dry powder inhaler for the treatment of lung conditions such as asthma. For dermatological or ophthalmic indications, the composition will be suitable for application to the skin or mucous membranes formulated as a cream, ointment or solution. Such compositions form a further aspect of the invention.

The dosage of the inhibitor compound of the invention will depend upon the nature and severity of the condition being treated, the administration route and the size and species of the patient. However, in general, quantities to be administered are from 0.1 to 1000 mgs per day, preferably, 1 to 100 mgs per day. Conveniently, a suitable dosage, e.g. 20mgs, can be administered by inhalation three times daily.

Thus, viewed from a further aspect the invention provides a method of treatment of human or non-human animal body (e.g. mammalian, avian or reptilian body) to combat a condition responsive to a tryptase inhibitor, said method comprising administering to said body an effective amount of a tryptase inhibitor according to the invention.

In a preferred embodiment the tryptase inhibitors of the invention can be administered along with other

- 16 -

active ingredients suitable for use in treating asthma, for example beta-adrenoceptor agonists such as salbutamol or anti-inflammatory agents such as corticosteroids e.g. beclomethasone or cromolyns. It is envisaged that the tryptase inhibitors of the invention and the other active ingredient may act synergistically together. In a preferred embodiment the compounds of the invention are administered in conjunction with corticosteroids to reduce the dose of the steroid hence minimising steroid associated side effects.

Thus, viewed from a yet further aspect the invention provides a pharmaceutical composition comprising a compound of formula (I), together with one or more anti-asthma agents together with at least one pharmaceutically acceptable excipient.

It is envisaged that the compounds of the invention will be of use in combating mast cell mediated diseases such as asthma, allergic rhinitis, skin conditions such as eczema, atopic dermatitis and urticaria, rheumatoid arthritis, conjunctivitis and inflammatory bowel disease.

Although not wanting to be bound by any theory, it is expected that a tryptase inhibitor will be primarily administered chronically as prophylaxis to prevent or diminish exacerbations of the disease. However, for some diseases a more acute relief of symptoms may also be achievable.

For all the above conditions the compounds of the invention could be used alone or along side existing treatments and therapies.

The invention will now be described with reference to the following non-limiting examples.

Experimental

35

Abbreviations used follow IUPAC-IUB nomenclature. Additional abbreviations are Hplc, high-performance

- 17 -

liquid chromatography; MALDI-TOF, matrix assisted laser desorption ionisation - time of flight; rt, retention time; nmr, nuclear magnetic resonance. Alcohols and 4-aminomethylbenzoic acid were purchased from Aldrich (Gillingham, UK), Lancaster (Morecombe, UK), Avocado (Heysham, UK) or Ubichem.

Purification: Flash column chromatography¹ was carried out using Merck silica gel Si60 (40-63mm, 230-400 mesh).

Analysis: Proton nuclear magnetic resonance (¹H) spectra were recorded on Bruker DPX300 (300MHz). Analytical Hplc was on a Shimadzu LC6 gradient system equipped with an autosampler. Eluant A consisted of aqueous TFA (0.1%) and eluant B 90% MeCN in aqueous TFA (0.1%) with gradient elution (Gradient 1, 0min 20%B then 20%B to 100%B over 15min then 100%B for 5min; Gradient 2, 0min 20%B then 20%B to 100%B over 11 min; Gradient 3, 0min 50%B then 50%B to 100%B over 14min). Columns used were Jupiter 5 C18 column (2.1x150mm, 5µm particle size) and SymmetryShield RP₈ column (2.1x50mm, 3.5µm particle size). Purified products were further analysed by MALDI-TOF.

Example 1

Preparation of 2'-Naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt

t-Butyloxycarbonylaminomethyl benzoic acid² (500mg, 2.0mmol) dissolved in dichloromethane (5ml) was treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (420mg, 2.2mmol). After stirring for 10 minutes 2-naphthol (316mg, 2.2mmol) and a catalytic amount of N,N-dimethylaminopyridine were added. The resulting solution was stirred overnight at room temperature. After dilution with dichloromethane (20ml) the mixture was washed with saturated aqueous citric acid (25ml), saturated aqueous sodium bicarbonate (25ml)

water/acetonitrile/TFA) rt 10.88min.

Example 7

4'-Methoxyphenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.26 (2H, d, J=8.3Hz, 2-H, 6-H);
7.66 (2H, d, J=8.3Hz, 3-H, 5-H); 7.16 (2H, d, J=9.1Hz,
2'-H, 6'-H); 7.00 (2H, d, J=9.1Hz, 3'-H, 5'-H);
4.25 (2H, s, 4-CH₂); 3.83 (3H, s, OMe). M.S.TOF 258
(M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 11.84min. Hplc (SymmetryC8,
Gradient 5, water/acetonitrile/TFA) rt 9.00min.

Example 8

6'-Bromo-2'-naphthyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.15 (2H, d, J= 8.4Hz, 2-H, 6-H);
7.99 (1H, d, J=1.9Hz, 5'H); 7.78 (1H, d, J=9.0Hz, 4'-H);
7.67 (1H, d, J=8.8Hz, 8'-H); 7.61 (1H, d, J=2.2Hz, 1'-
H); 7.52 (2H, d, J=8.4Hz, 3-H, 5-H); 7.48 (1H, dd,
J=8.8, 1.9Hz, 7'-H); 7.29 (1H, dd, J= 9.0, 2.2Hz, 3'-H);
4.11 (2H, s, 4-CH₂). M.S. TOF 357 (M+1)⁺. Hplc (Jupiter5
C18, Gradient 1, Water/acetonitrile/TFA) rt 19.8 min.
Hplc (SymmetryC8 Gradient 2, Water/acetonitrile/TFA) rt
10.93 min.

Example 9

7'-Methoxy-2'-naphthyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.32 (2H, d, J=8.3Hz, 2-H, 6-H);
7.87 (1H, d, J=8.8Hz, 4'-H); 7.82 (1H, d, J=9.0Hz, 5'-
H); 7.69 (2H, d, J=8.3Hz, 3-H, 5-H); 7.65 (1H, d,
J=2.2Hz, 1'-H); 7.28 (1H, d, J=2.4Hz, 8'-H); 7.21 (1H,
dd, J=8.8, 2.2Hz, 3'-H); 7.17 (1H, dd, J=9.0, 2.4, 6'-
H); 4.28 (2H, s, 4-CH₂); 3.93 (3H, s, 7'-OMe). M.S. TOF
308 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
Water/acetonitrile/TFA) rt 16.57 min. Hplc (SymmetryC8

- 18 -

and water (25ml), then dried over magnesium sulphate and concentrated under reduced pressure. The crude product was purified by flash column chromatography (10% - 30% ethyl acetate/hexane) to yield the 2'-naphthyl-4-(t-butyloxycarbonylaminomethyl)benzoate as a thick oil
5 (620mg, 82% yield).

The deprotection was effected by dissolution in a mixture of trifluoroacetate (5ml) and dichloromethane (5ml). After stirring for 1 hour the mixture was
10 concentrated under reduced pressure. Trituration with diethyl ether afforded 2'-naphthyl 4-(aminomethyl)benzoate trifluoroacetic acid salt (580mg, 75% yield).

15. ¹H nmr (d₄ methanol) 8.20 (2H, d, J=8.2Hz, 2-H, 6-H); 8.05-7.60 (3H, m, Ar); 7.58 (2H, d, J=8.2Hz, 3-H, 5-H); 7.45-7.20 (4H, m, Ar); 4.18 (2H, s, 4-CH₂). M.S.TOF 278 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 16.6 min. Hplc (Symmetry C8,
20 Gradient 2, water/acetonitrile/TFA) rt 10.5 min.

Further examples were synthesised in an analagous manner using alcohols either commercially available or prepared using standard literature procedures. In several cases
25 the deprotection step was effected using hydrogen chloride dissolved in diethyl ether to afford the products as hydrochloride salts.

Example 2

30 **1'-Naphthyl 4-(aminomethyl)benzoate hydrochloride salt**
¹H nmr (d₄ methanol) 8.41 (2H, d, J=8.4Hz, 2-H, 6-H); 7.99 (1H, d, J=7.5Hz, Ar); 7.88 (2H, d, J=8.0Hz, Ar); 7.75 (2H, d, J=8.4Hz, 3-H, 5-H); 7.57 (3H, m, Ar); 7.40 (1H, m, Ar); 4.29 (2H, s, 4-CH₂). M.S.TOF 278 (M+1)⁺.
35 Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 16.03min. Hplc (SymmetryC8, Gradient 2, water/acetonitrile/TFA) rt 10.43min.

Example 3**Phenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.27 (2H, d, J=8.3Hz, 2-H, 6-H);
7.68 (2H, d, J=8.3Hz, 3-H, 5-H); 7.52-7.20 (5H, m, Ph);
5 4.26 (2H, s, 4-CH₂). M.S.TOF 228 (M+1)⁺. Hplc (Jupiter5
C18, Gradient 1, water/acetonitrile/TFA) rt 11.4 min.
Hplc (Symmetry C8, Gradient 2, water/acetonitrile/TFA) rt
9.6 min.

Example 4**4'-Nitrophenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₆ DMSO) 8.58 (3H, bs, NH₃⁺); 8.31-7.95 (4H, m,
Ar); 7.85-7.30 (4H, m, Ar); 4.08 (2H, m, 4-CH₂). M.S.TOF
15 273 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 12.2 min. Hplc (Symmetry C8,
Gradient 2, water/acetonitrile/TFA) rt 9.9 min.

Example 5**4'-Chlorophenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₆ DMSO) 8.59 (3H, bs, NH₃⁺); 8.25 (2H, m, 2-H, 6-
H); 7.80 (2H, m, 3'-H, 5'-H); 7.59 (2H, m, 3-H, 5-H);
7.40 (2H, m, 2'-H, 6'-H); 4.20 (2H, bs, 4-CH₂). M.S.TOF
25 262.5 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 14.8 min. Hplc (Symmetry C8,
Gradient 2, water/acetonitrile/TFA) rt 10.2 min.

Example 6**1'-Bromo-2'-naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.27 (2H, d, J=8.4Hz, 2-H, 6-H); 8.20
(1H, d, J=8.5Hz, Ar); 7.92 (2H, m, Ar); 7.61 (2H, d,
J=8.4Hz, 3-H, 5-H); 7.54 (2H, m, Ar); 7.38 (1H, d,
J=8.9Hz, Ar); 4.18 (2H, s, 4-CH₂). M.S.TOF 357 (M+1)⁺.
35 Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA)
rt 18.28min. Hplc (SymmetryC8, Gradient 2,

- 21 -

Gradient 2, Water/acetonitrile/TFA) rt 10.63 min.

Example 10**4'-Cyanophenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.29 (2H, d, J=8.3Hz, 2-H, 6-H);
7.87 (2H, d, J= 11.2Hz, 3'-H, 5'-H); 7.69 (2H, d,
J=8.3Hz, 3-H, 5-H); 7.50 (2H, d, J=11.2Hz, 2'-H, 6'-H);
4.28 (2H, s, 4-CH₂); M.S. TOF 253 (M+1)⁺. Hplc (Jupiter5
C18, Gradient 1, Water/acetonitrile/TFA) rt 9.99 min.
Hplc (SymmetryC8 Gradient 2, Water/acetonitrile/TFA) rt
9.38 min.

Example 11**3'-Chlorophenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.27 (2H, d, J=8.3Hz, 2-H, 6-H);
7.67 (2H, d, J=8.3Hz, 3-H, 5-H); 7.50-7.44 (1H, dd,
J=8.5, 8.2Hz, 5'-H); 7.38-7.33 (2H, m, Ar); 7.25-7.21
(1H, m, Ar); 4.27 (2H, s, 4-CH₂). M.S. TOF 263 (M+1)⁺.
Hplc (Jupiter5 C18, Gradient 1, Water/acetonitrile/TFA)
rt 14.71 min. Hplc (SymmetryC8 Gradient 2,
Water/acetonitrile/TFA) rt 11.29 min.

Example 12**6'-Methoxycarbonyl-2'-naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.80 (1H, s, 5'-H); 8.45 (2H, d,
J=8.3Hz, 2-H, 6-H); 8.23 (2H, m, 7'-H, 8'-H); 8.10 (1H,
d, J=8.7Hz, 3'-H); 7.97 (1H, d, J=2.2Hz, 1'-H); 7.81
(2H, d, J=8.3Hz, 3-H, 5-H); 7.62 (1H, dd, J=8.7, 2.2Hz,
4'-H); 4.40 (2H, s, 4-CH₂); 4.18 (3H, s, 6'-CO₂Me).
M.S.TOF 36 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 16.1 min. Hplc (Symmetry C8,
Gradient 2, water/acetonitrile/TFA) rt 10.5 min.

Example 13

- 22 -

3'-Methoxycarbonyl-2'-naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.70 (1H, s, 1'-H); 8.31 (2H, d, J=8.4Hz, 2-H, 6-H); 8.09 (1H, d, J=8.2Hz, 8'-H); 7.97 (1H, d, J=7.9Hz, 5'-H); 7.78 (1H, s, 4'-H); 7.76-7.60 (4H, m, Ar); 4.28 (2H, s, 4-CH₂); 3.80 (3H, s, 3'-CO₂Me). M.S.TOF 336 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 16.4 min. Hplc (Symmetry C8, Gradient 2, water/acetonitrile/TFA) rt 10.4 min.

Example 14

1'-Methoxycarbonyl-2'-naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.08 (2H, d, J=7.9Hz, 2-H, 6-H); 8.02 (1H, d, J=9.0Hz, 3'-H); 7.95- 7.85 (2H, m, 5'-H, 8'-H); 7.60 (2H, d, J=7.9Hz, 3-H, 5-H); 7.50 (2H, m, 6'-H, 7'-H); 7.38 (1H, d, J=9.0Hz, 4'-H); 4.25 (2H, s, 4-CH₂); 3.78 (3H, s, 1'-CO₂Me). M.S.TOF 336 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 16.6 min. Hplc (Symmetry C8, Gradient 2, water/acetonitrile/TFA) rt 10.4 min.

Example 15

5',6',7',8'-Tetrahydro-2-naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.13 (2H, d, J=8.4Hz, 2-H, 6-H); 7.54 (2H, d, J=8.4Hz, 3-H, 5-H); 7.01 (1H, d, J=9.0Hz, Ar); 6.81 (2H, m, Ar); 4.12 (2H, s, 4-CH₂); 2.70 (4H, m, 5'-H, 8'-H); 1.73 (4H, m, 6'-H, 7'-H). M.S.TOF 282 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 17.84min. Hplc (SymmetryC8, Gradient 2, water/acetonitrile/TFA) rt 10.75min.

Example 16

6'-Quinoliny 4-(aminomethyl)benzoate dihydrochloride salt

¹H nmr (d₄ methanol) 9.46 (2H, m, Ar); 8.61 (1H, d,

- 23 -

J=9.3Hz, Ar); 8.54 (3H, m, Ar); 8.37 (2H, m, Ar); 7.93 (2H, d, J=8.3Hz, 3-H, 5-H); 4.48 (2H, s, 4-CH₂). M.S.TOF 279 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 7.07min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 3.44min.

Example 17**3'-iso-Propylphenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.16 (2H, d, J=8.4Hz, 2-H, 6-H); 7.57 (2H, d, J=8.4Hz, 3-H, 5-H); 7.27 (1H, t, J=7.8Hz, 5'-H); 7.09 (1H, d, J=7.8Hz, 6'-H); 7.00 (1H, m, 2'-H); 6.93 (1H, m, 4'-H); 4.17 (2H, s, 4-CH₂); 2.88 (1H, sep, J=6.9Hz, 3'-CH); 1.08 (6H, d, J=6.9Hz, 3'-CMe₂). M.S.TOF 270 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 17.6 min. Hplc (Symmetry C8, Gradient 2, water/acetonitrile/TFA) rt 10.6 min.

Example 18**4'-Biphenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.18 (2H, d, J=8.3Hz, 2-H, 6-H); 7.61 (2H, d, J=8.3Hz, 3-H, 5-H); 7.57-7.17 (9H, m, Ar); 4.18 (2H, s, 4-CH₂). M.S.TOF 304 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 18.9 min. Hplc (Symmetry C8, Gradient 2, water/acetonitrile/TFA) rt 10.8 min.

Example 19**4'-(t-Butyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.15 (2H, d, J=8.4Hz, 2-H, 6-H); 7.55 (2H, d, J=8.4Hz, 3-H, 5-H); 7.38 (2H, d, J=8.8Hz, 2'-H, 6'-H); 7.08 (2H, d, J=8.8Hz, 3'-H, 5'-H); 4.18 (2H, s, 4-CH₂); 1.26 (9H, s, 4'-tBu). M.S.TOF 284 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 19.5 min. Hplc (Symmetry C8, Gradient 2,

- 24 -

water/acetonitrile/TFA) rt 10.9 min.

Example 20

**7'-Hydroxy-2'-naphthyl 4-(aminomethyl)benzoate
hydrochloride salt**

¹H nmr (d₄ methanol) 8.32 (2H, d, J=8.3Hz, 2-H, 6-H);
7.84 (1H, d, J= 8.9Hz, 4'-H); 7.78 (1H, d, J=8.7Hz, 5'-
H); 7.69 (2H, d, J=8.3Hz, 3-H, 5-H); 7.51 (1H, d,
J=2.2Hz, 1'-H); 7.18-7.08 (3H, m, 3'-H, 6'-H, 8'-H);
4.28 (2H, s, 4-CH₂). M.S. TOF 294 (M+1)⁺. Hplc (Jupiter5
C18, Gradient 1, Water/acetonitrile/TFA) rt 12.75 min.
Hplc (SymmetryC8 Gradient 2, Water/acetonitrile/TFA) rt
10.00 min.

Example 21

**4'-iso-Propylphenyl 4-(aminomethyl)benzoate
hydrochloride salt**

¹H nmr (d₄ methanol) 8.26 (2H, d, J=8.4Hz, 2-H, 6-H);
7.67 (2H, d, J=8.4Hz, 3-H, 5-H); 7.34 (2H, d, J=8.6Hz,
2'-H, 6'-H); 7.15 (2H, d, J=8.6Hz, 3'-H, 5'-H); 4.26
(2H, s, 4-CH₂); 2.98 (1H, sep, J= 6.8Hz, 4'-CH); 1.30
(6H, d, J=6.8Hz, 4'-CMe₂). M.S. TOF 270 (M+1)⁺. Hplc
(Jupiter5 C18, Gradient 1, Water/acetonitrile/TFA) rt
18.27 min. Hplc (SymmetryC8 Gradient 2,
Water/acetonitrile/TFA) rt 10.70 min.

Example 22

**4'-Benzylphenyl 4-(aminomethyl)benzoate hydrochloride
salt**

¹H nmr (d₄ methanol) 8.38 (2H, d, J=8.3Hz, 2-H, 6-H);
7.78 (2H, d, J=8.3Hz, 3-H, 5-H); 7.45-7.25 (9H, m, Ar);
4.38 (2H, s, 4-CH₂); 4.15 (2H, s, 4'-CH₂). M.S. TOF 318
(M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
Water/acetonitrile/TFA) rt 19.80 min. Hplc (SymmetryC8
Gradient 2, Water/acetonitrile/TFA) rt 10.96 min.

Example 23

3'-Methoxyphenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.11 (2H, d, J=8.3 Hz, 2-H, 6-H);
7.51 (2H, d, J=8.3 Hz, 3-H, 5-H); 7.24-7.18 (1H, m, 5'-
5 H); 6.76-6.65 (3H, m, 2'-H, 4'-H, 6'-H); 4.11 (2H, s, 4-
CH₂); 3.68 (3H, s, 3'-OMe). M.S. TOF 258 (M+1)⁺. Hplc
(Jupiter5 C18, Gradient 1, Water/acetonitrile/TFA) rt
12.56 min. Hplc (SymmetryC8 Gradient 2,
Water/acetonitrile/TFA) rt 9.69 min.

10

Example 24

8'-Methoxycarbonyl-2'-naphthyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.88 (1H, d, J=9.4Hz, 4'-H); 8.19
15 (2H, d, J=8.4Hz, 2-H, 6-H); 8.10 (1H, d, J=8.3Hz, Ar);
8.10 (1H, dd, J=7.3, 1.1Hz, Ar); 8.02 (1H, d, J=8.3Hz,
Ar); 7.72 (1H, d, J=2.4Hz, 1'-H); 7.57 (2H, d, J=8.4Hz,
3-H, 5-H); 7.49 (1H, m, Ar); 7.42 (1H, dd, J=9.4, 2.4Hz,
3'-H); 4.18 (2H, s, 4-CH₂); 3.90 (3H, s, 5'-CO₂Me).
20 M.S.TOF 336 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 16.6 min. Hplc (Symmetry C8,
Gradient 2, water/acetonitrile/TFA) rt 10.5 min.

Example 25

25 1'-Amino-2'-naphthyl 4-(aminomethyl)benzoate dihydrochloride salt

¹H nmr (d₆ DMSO) 8.59 (3H, bs, 1'-NH); 8.47 (1H, d,
J=8.1Hz, Ar); 8.32 (2H, d, J=8.2Hz, 2-H, 6-H); 8.15 (1H,
d, J=8.2Hz, Ar); 8.01 (2H, s, Ar); 7.77 (3H, d, J=8.2Hz,
30 Ar); 7.64 (1H, t, J=7.1Hz, Ar); 4.15 (2H, s, 4-CH₂).
M.S.TOF 294 (M+2)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 15.57min. Hplc (SymmetryC8,
Gradient 5, water/acetonitrile/TFA) rt 8.65min

35 Example 26

7'-Quinolinyl 4-(aminomethyl)benzoate dihydrochloride salt

- 26 -

¹H nmr (d₄ methanol) 9.15 (1H, d, J=4.1Hz, Ar); 8.98 (1H, d, J=8.2Hz, Ar); 8.36 (3H, d, J=8.3Hz, Ar); 8.18 (1H, d, J=1.5Hz, Ar); 7.94 (1H, dd, J=8.3, 5.0Hz, Ar); 7.85 (1H, m); 7.74 (2H, d, J=8.2Hz, 3-H, 5-H); 4.29 (2H, s, 4-CH₂).

5 M.S.TOF 282 (M+2)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 2.15min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 4.76min.

Example 27

10 3'-(t-Butyl)phenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.17 (2H, d, J=8.3Hz, 2-H, 6-H); 7.56 (2H, d, J=8.3Hz, 3-H, 5-H); 7.27 (2H, m, Ar); 7.14 (1H, m, Ar); 6.93 (1H, m, Ar); 4.16 (2H, s, 4-CH₂); 1.24 (9H, s, 3'-t-Bu). M.S.TOF 284 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 18.78min. Hplc (SymmetryC8, Gradient 2, water/acetonitrile/TFA) rt 10.85min.

20 Example 28

3'-Biphenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.31 (2H, d, J=8.4Hz, 2-H, 6-H); 8.12 (2H, d, J=7.8Hz, Ar); 7.74-7.23 (7H, m, Ar); 7.01 (2H, d, J=7.7Hz, Ar); 4.28 (2H, s, 4-CH₂). M.S.TOF 304 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 18.57min. Hplc (SymmetryC8, Gradient 2, water/acetonitrile/TFA) rt 10.90min.

Example 29

30 4'-Phenoxyphenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 7.93 (2H, d, J=8.3Hz, 2-H, 6-H); 7.58 (2H, d, J=9.0Hz, Ar); 7.51 (2H, d, J=8.3Hz, 3-H, 5-H); 7.25 (2H, m, Ar); 7.01 (1H, m, Ar); 6.91 (4H, m, Ar); 4.11 (2H, s, 4-CH₂). M.S.TOF 320 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 16.55min. Hplc (SymmetryC8, Gradient 2,

- 27 -

water/acetonitrile/TFA) rt 10.55min.

Example 30**3'-Phenoxyphenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 7.90 (2H, d, J=8.2Hz, 2-H, 6-H);
7.50 (2H, d, J=8.2Hz, 3-H, 5-H); 7.4-7.2 (5H, m, Ar);
7.03 (1H, t, J=7.4Hz, Ar); 6.93 (2H, d, J=7.7Hz, Ar);
6.68 (1H, m, Ar); 4.11 (2H, s, 4-CH₂). M.S.TOF 320
(M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 16.82min. Hplc (SymmetryC8,
Gradient 2, water/acetonitrile/TFA) rt 10.48min.

Example 31**5'-Amino-2'-naphthyl 4-(aminomethyl)benzoate ditrifluoroacetic acid salt**

¹H nmr (d₄ methanol) 8.21 (2H, d, J=8.3Hz, 2-H, 6-H);
7.98 (1H, d, J=9.2Hz, Ar); 7.71 (1H, d, J=2.3Hz, 1'-H);
7.63 (1H, d, J=8.4Hz, Ar); 7.58 (2H, d, J=8.3Hz, 3-H, 5-H);
7.40 (2H, m, Ar); 7.21 (1H, m, Ar); 4.15 (2H, s, 4-CH₂). M.S.TOF 293 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 4.3min. Hplc (Symmetry C8,
Gradient 3, water/acetonitrile/TFA) rt 7.5 min.

Example 32**8'-Amino-2'-naphthyl 4-(aminomethyl)benzoate ditrifluoroacetate salt**

¹H nmr (d₄ methanol) 8.20 (2H, d, J=8.4Hz, 2-H, 6-H);
7.82 (1H, d, J=9.0Hz, Ar); 7.78 (1H, d, J=2.2Hz, 1'-H);
7.58 (2H, d, J=8.4Hz, 3-H, 5-H); 7.42 (1H, d, J=8.3Hz, Ar);
7.27 (2H, m, Ar); 6.98 (1H, m, Ar); 4.15 (2H, s, 4-CH₂). M.S.TOF 292 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
water/acetonitrile/TFA) rt 8.4 min. Hplc (Symmetry C8,
Gradient 3, water/acetonitrile/TFA) rt 7.4 min.

Example 33**5'-Quinoliny 4-(aminomethyl)benzoate ditrifluoroacetate**

salt

¹H nmr (d₄ methanol) 8.97 (1H, d, J=4.3Hz, Ar); 8.59 (1H, d, J=8.5Hz, Ar); 8.30 (2H, d, J=8.1Hz, 2-H, 6-H); 8.01 (1H, d, J=8.6Hz, Ar); 7.91 (1H, t, J=8.1Hz, Ar); 7.70-7.60 (2H, m, Ar); 7.63 (2H, d, J=8.1Hz, 3-H, 5-H); 4.20 (2H, s, 4-CH₂). M.S. TOF 279 (M+1)⁺. HPLC (Jupiter5 C18, water/acetonitrile/TFA, gradient 2) rt 9.83 min.

Example 34

10 **8'-Quinolinylnyl 4-(aminomethyl)benzoate dihydrochloride salt**

¹H nmr (d₄ methanol) 9.12 (1H, dd, J=1.4, 8.4Hz, Ar); 9.06 (1H, dd, J=1.4, 5.2Hz, Ar); 8.33 (2H, d, J=8.4Hz, 2-H, 6-H); 8.19 (1H, dd, J=1.7, 7.9Hz, Ar); 8.03-7.92 (3H, m, Ar); 7.65 (2H, d, J=8.4Hz, 3-H, 5-H); 4.21 (2H, s, 4-CH₂). M.S. TOF 279 (M+1)⁺. HPLC (Jupiter5 C18, water/acetonitrile/TFA, gradient 2) rt 11.95 min.

Example 35

20 **5'-Isoquinolinylnyl 4-(aminomethyl)benzoate dihydrochloride salt**

¹H nmr (d₄ methanol) 9.84 (1H, s, 1'-H); 8.69 (1H, d, J=6.6Hz, Ar); 8.58 (2H, m, Ar); 8.47 (2H, d, 8.4Hz, 2-H, 6-H); 8.29 (1H, dd, J=6.7, 7.8Hz, Ar); 8.20 (1H, d, J=7.9Hz, 4'-H); 7.81 (2H, d, J=8.4Hz, 2-H, 5-H); 4.21 (2H, s, 4-CH₂). M.S. TOF 279 (M+1)⁺. HPLC (Jupiter5 C18, water/acetonitrile/TFA, gradient 2) rt 9.79 min.

Example 36

30 **4'-Quinolinylnyl 4-(aminomethyl)benzoate dihydrochloride salt**

¹H nmr (d₄ methanol) 9.22 (1H, d, J=6.4Hz, 2'-H); 8.50 (1H, d, J=8.4Hz, Ar); 8.37 (2H, d, J=8.3Hz, 2-H, 6-H); 8.25 (1H, d, J=6.3Hz, 3'-H); 8.22-8.17 (2H, m, Ar); 8.00-7.94 (1H, m, Ar); 7.70 (2H, d, J=8.3Hz, 3-H, 5-H), 4.23 (2H, s, 4-CH₂). M.S. TOF 279 (M+1)⁺. HPLC (Jupiter5 C18, water/acetonitrile/TFA, gradient 2) rt 9.45 min.

Example 37**3'-Pyridyl 4-(aminomethyl)benzoate dihydrochloride salt**

¹H nmr (d₄ methanol) 8.98 (1H, d, J=2.2Hz, 2'-H); 8.72 (1H, d, J=5.4Hz, 4'-H); 8.53-8.49 (1H, m, 6'-H); 8.25 (2H, d, J=8.5Hz, 2-H, 6-H); 8.07 (1H, dd, J=5.6, 8.7Hz, 5'-H); 7.62 (2H, d, J=8.5Hz, 3-H, 5-H); 4.18 (2H, s, 4-CH₂). M.S. TOF 229 (M+1)⁺. HPLC (Jupiter5 C18, water/acetonitrile/TFA, gradient 2) rt 7.26 min.

Example 38**3'-(N-Morpholino)carbonylphenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.17 (2H, d, J=8.2Hz, 2-H, 6-H); 7.58 (2H, d, J=8.2Hz, 3-H, 5-H); 7.48 (1H, m, Ar); 7.30 (1H, d, J=1.5Hz, Ar); 7.27 (2H, s, Ar); 4.13 (2H, s, 4-CH₂); 3.7-3.3 (8H, m, 3'-N(CH₂CH₂)₂). M.S.TOF 341 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 4.97min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 7.66min.

20

Example 39**4'-(N-Morpholino)carbonylphenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.05 (2H, d, J=8.3Hz, 2-H, 6-H); 7.49 (2H, d, J=8.3Hz, 3-H, 5-H); 7.36 (2H, d, J=8.5Hz, 3'-H, 5'-H); 7.17 (2H, d, J=8.5Hz, 2'-H, 6'-H); 4.06 (2H, s, 4-CH₂); 3.6-3.2 (8H, m, 4'-N(CH₂CH₂)₂). M.S.TOF 341 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 3.77min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 7.69min.

30

Example 40**2'-(N-Morpholino)carbonylphenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.06 (2H, d, J=8.3Hz, 2-H, 6-H); 7.50 (2H, d, J=8.3 Hz, 3-H, 5-H); 7.41 (1H, m, Ar); 7.25 (3H, m, Ar); 4.07 (2H, s, 4-CH₂); 3.6-3.1 (8H, m, 2'-

35

$N(CH_2CH_2)_2$. M.S.TOF 341 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 5.66min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 7.80min.

5

Example 41

3'-((N-Morpholino)carbonylmethyl)phenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.50 (2H, d, J=8.3Hz, 2-H, 6-H);
10 7.92 (2H, d, J=8.3Hz, 3-H, 5-H); 7.67 (1H, m, Ar); 7.48 (1H, d, J=7.6Hz, Ar); 7.40 (2H, d, J=8.0Hz, Ar); 4.50 (2H, s, 3'-CH₂); 4.09 (2H, s, 4-CH₂); 3.9-3.7 (8H, m, 3'-N(CH₂CH₂)₂). M.S.TOF 355 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 6.54min. Hplc
15 (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 7.76min.

Example 42

4'-((N-Morpholino)carbonylmethyl)phenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.15 (2H, d, J=8.3Hz, 2-H, 6-H);
20 7.55 (2H, d, J=8.3Hz, 3-H, 5-H); 7.26 (2H, d, J=8.6Hz, Ar); 7.11 (2H, d, J=8.6Hz, Ar); 4.14 (2H, s, 4-CH₂); 3.71 (2H, s, 4'-CH₂); 3.7-3.3 (8H, m, 4'-N(CH₂CH₂)₂). M.S.TOF
25 355 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 5.93min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 7.71min.

Example 43

2'-((N-Morpholino)carbonylmethyl)phenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.21 (2H, s, Ar); 7.67 (2H, s, Ar);
30 7.35 (2H, m, Ar); 7.26 (2H, m, Ar); 4.21 (2H, s, 4-CH₂); 3.75 (2H, s, 2'-CH₂); 3.6-3.3 (8H, m, 2'-N(CH₂CH₂)₂).
35 M.S.TOF 355 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, water/acetonitrile/TFA) rt 5.68min. Hplc (SymmetryC8, Gradient 5, water/acetonitrile/TFA) rt 8.58min.

Example 44**2'-Biphenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

- 5 ¹H nmr (d₄ methanol) 8.08 (2H, d, J=8.3Hz, 2-H, 6-H);
7.57 (2H, d, J=8.3Hz, 3-H, 5-H); 7.51-7.39 (5H, m, Ar);
7.33-7.21 (4H, m, Ar); 4.21 (2H, s, 4-CH₂); M.S. TOF 304
(M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
Water/acetonitrile/TFA) rt 16.04 min. Hplc (SymmetryC8
10 Gradient 2, Water/acetonitrile/TFA) rt 10.54 min.

Example 45**2'-(t-Butyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

- 15 ¹H nmr (d₄ methanol) 8.30 (2H, d, J=8.4Hz, 2-H, 6-H);
7.70 (2H, d, J=8.4Hz, 3-H, 5-H); 7.53-7.48 (1H, m, 6'-
H); 7.33- 7.21 (2H, m, 5'-H, 4'-H); 7.05-7.11 (1H, m,
3'-H); 4.28 (2H, s, 4-CH₂); 1.38 (9H, s, 2'-t-Bu); M.S.
TOF 284 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1,
20 Water/acetonitrile/ TFA) rt 16.64 min. Hplc (SymmetryC8
Gradient 2, Water/acetonitrile/TFA) rt 10.69 min.

Example 46**4'-(2-Phenylethenyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

- 25 ¹H nmr (d₄ methanol) 8.16 (2H, d, J=8.3Hz, 2-H, 6-H);
7.57-7.07 (13H, m, Ar, CH=CH); 4.15 (2H, s, 4-CH₂). M.S.
TOF 330 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 8,
Water/acetonitrile/TFA) rt 13.47 min. Hplc (SymmetryC8
30 Gradient 2, Water/acetonitrile/TFA) rt 11.31 min.

Example 47**4'-(2-Phenylethyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

- 35 ¹H nmr (d₄ methanol) 8.14 (2H, d, J=8.3Hz, 2-H, 6-H);
7.57 (2H, d, J=8.3Hz, 3-H, 5-H); 7.18-6.97 (9H, m, Ar);
4.15 (2H, s, 4-CH₂); 2.84 (4H, s, 4'-CH₂CH₂). M.S. TOF

- 32 -

332 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 8, Water/acetonitrile/TFA) rt 13.47 min. Hplc (SymmetryC8, Gradient 2, Water/acetonitrile/TFA) rt 11.25 min.

5 **Example 48**

2'-Nitrophenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.16 (2H, d, J=8.1, 2-H, 6-H); 8.09 (1H, dd, J=1.0, 8.1Hz, 3'-H); 7.73 (1H, t, J=7.2Hz, 5'-H); 7.59 (2H, d, J=8.1Hz, 3-H, 5-H); 7.46 (1H, t, J=7.8Hz, 4'-H); 7.41 (1H, d, J=8.0Hz, 6'-H); 4.17 (2H, s, 4-CH₂). M.S. TOF 273 (M+1)⁺. HPLC (Jupiter5 C18, water/acetonitrile/TFA, gradient 2) rt

15 **Example 49**

2'-Cyanophenyl 4-(aminomethyl)benzoate hydrochloride salt

¹H nmr (d₄ methanol) 8.21 (2H, d, J=8.4Hz, 2-H, 6-H); 7.77-7.67 (2H, m, Ar); 7.59 (2H, d, J=8.4Hz, 3H, 5H); 7.46-7.36 (2H, m, Ar); 4.17 (2H, s, 4-CH₂). M.S. TOF 253 (M+1)⁺.

Example 50

25 **2'-Methylphenyl 4-(aminomethyl)benzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.17 (2H, d, J=8.2Hz, 2-H, 6-H); 7.59 (2H, d, J=8.2Hz, 3-H, 5-H); 7.23-7.01 (4H, m, Ar); 4.16 (2H, s, 4-CH₂). M.S. TOF 242 (M+1)⁺

30 The following examples were prepared in a similar manner. Suitably protected alcohols were bought or synthesised by conventional means and aminomethylbenzoic acid was purchased and used as previously described.

35 **Analysis:** Proton nuclear magnetic resonance (¹H) spectra were recorded on Bruker DPX300 (300MHz). Analytical Hplc was on a Shimadzu LC6 gradient system equipped with an

- 33 -

autosampler. Eluant A consisted of aqueous TFA (0.1%) and eluant B 90% MeCN in aqueous TFA (0.1%) with gradient elution (Gradient 4, 0min 20%B then 20%B to 53.3%B over 15min the 53.3%B for 1min then 100%B for 1min; Gradient 5, 0min 20%B then 20%B to 100%B over 15min then 100%B for 5min; Gradient 6, 0min 20%B then 20%B to 100%B over 5 min then 100%B for 1min). Columns used were Magellan C8 column (2.1 x 150mm, 5µm particle size) and Magellan C18 column (4.6 x 30mm, 3µm particle size). Purified products were further analysed by LC-MS (PESCIEX Single Quadropole API-150EX).

Example 51

4-(Methoxycarbonylmethyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.25 (2H, d); 7.65 (2H, d); 7.38 (2H, d); 7.20 (2H, d); 4.29 (2H, s); 3.72 (5H, s) M.S.TOF 300 (M+1)⁺, Hplc (Magellan C8, Gradient 4, water/acetonitrile/TFA) rt 12.06min, LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 2.27min, 300 (M+1)⁺.

Example 52

4-[(2-Acetylamino-2-carboxy)ethyl]phenyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.00 (2H, d); 7.43 (2H, d); 6.98 (2H, d); 4.48 (1H, m); 4.0 (2H, s); 3.01 (1H, dd); 2.78 (1H, dd); 1.72 (3H, s). Hplc (magellan C8, Gradient 5, water/acetonitrile/TFA) rt 9.4min. LC-MS (magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.69min, 357 (M+1)⁺.

Example 53

4-[(N-Carboxymethyl)carboxamidol]phenyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.31 (2H, d); 8.02 (2H, d); 7.71 (2H, d); 7.42 (2H, d); 4.29 (2H, s); 4.16 (2H, s). Hplc

- 34 -

(Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 7.23 min. LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.45 min, 329 (M+1)⁺.

5 **Example 54**

4-(Carboxymethyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.27 (2H, d); 7.68 (2H, d); 7.39 (2H, d); 7.20 (2H, d); 4.24 (2H, s); 3.69 (2H, s), Hplc
10 (Magellan C8, Gradient 4, water/acetonitrile/TFA) rt 9.94min, LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.80min, 286 (M+1)⁺.

Example 55

15 **O-[Methyl N-acetyl-L_tyrosinyl] 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.22 (2H, d); 7.63 (2H, d); 7.31 (2H, d); 7.20 (2H, d); 4.72 (1H, m); 4.27 (2H, s); 3.69 (3H, s); 3.21 (3H, s); 3.21 (1H, dd); 3.01 (1H, dd);
20 2.92 (3H, s). Hplc (magellan C8, gradient 5, water/acetonitrile/TFA) rt 8.3min. LC-MS (magellan C18, Gradient 5, water/acetonitrile/TFA) rt 1.98 min, 371 (M+1)⁺.

25 **Example 56**

4-[N-[(Methoxycarbonyl)methyl]carboxamido]phenyl 4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.30 (2H, d); 7.95 (2H, d); 7.32 (2H, d); 4.28 (2H, s); 4.12 (2H, s); 3.71 (3H, s). Hplc
30 (magellan C8, Gradient 5, water/acetonitrile/TFA) rt 9.10min. LC-MS (magellan C18, Gradient 5, water/acetonitrile/TFA) rt 1.65min, 343 (M+1)⁺.

Example 57

35 **4-[4-Carboxypiperidin-1-oyl]phenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.10 (2H, d); 7.39 (2H, d); 7.32

- 35 -

(2H, d); 7.18 (2H, d); 4.32 (1H, m); 4.12 (2H, s); 3.65 (1H, m); 3.05 (2H, m); 2.60 (1H, m); 2.82 (2H, m); 1.50 (2H, m). Hplc (magellan C8, Gradient 5, water/acetonitrile/TFA) rt 8.4min. LC-MS (magellan C18, Gradient 5, water/acetonitrile/TFA) rt 1.69min, 383 (M+1)⁺.

Example 58

4-(2-Carboxypyrrolidin-1-oyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt
¹H nmr (d₄ methanol) 8.15 (2H, d); 7.58 (4H, m); 7.29 (2H, d); 4.53 (1H, m); 4.15 (2H, s); 3.70-3.50 (2H, m); 2.30 (1H, m); 2.10-1.80 (3H, m), Hplc (Magellan C8, Gradient 4, water/acetonitrile/TFA) rt 9.34min, LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.73min, 369 (M+1)⁺.

Example 59

4-[4-(Ethoxycarbonyl)piperidin-1-oyl]phenyl 4-(aminomethyl)benzoate trifluoroacetate salt
¹H nmr (d₄ methanol) 8.27 (2H, d); 7.62 (2H, d); 7.52 (2H, d); 7.39 (2H, d); 4.48 (1H, s); 4.29 (2H, s); 4.15 (2H, s); 3.77 (1H, m); 3.22 (2H, m); 2.73 (1H, m); 2.05 (2H, m); 1.70 (2H, m); 1.30 (3H, t). Hplc (magellan C8, Gradient 5, water/acetonitrile/TFA) rt 7.29 min. LC-MS (magellan C18, Gradient 5, water/acetonitrile/TFA) rt 2.41min, 411 (M+1)⁺.

Example 60

3-(4-Carboxypiperidin-1-oyl)phenyl 4-(aminomethyl)benzoate trifluoroacetate salt
¹H nmr (d₄ methanol) 8.32 (2H, d); 7.69 (2H, d); 7.62 (1H, t); 7.43-7.36 (3H, m); 4.56-4.45 (1H, m); 4.29 (2H, s); 3.86-3.74 (1H, m), 3.36-3.09 (2H, m); 2.75-2.64 (1H, m); 2.16-1.89 (2H, m); 1.82-1.96 (2H, m). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.03 min. LC-MS (Magellan C18, Gradient 6,

- 36 -

water/acetonitrile/TFA) rt 1.68 min, 383 (M+1)⁺.

Example 61**2-(4-Carboxypiperidin-1-oyl)phenyl 4-****5 (aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.23 (2H, d); 7.67 (2H, d); 7.62 (1H, m); 7.48-7.37 (3H, m); 4.45-4.30 (1H, m); 4.26 (2H, s); 3.67-3.57 (1H, m), 3.25-3.08 (1H, m); 2.99-2.87 (1H, m); 2.62-2.51 (1H, m); 1.95-1.81 (2H, m); 1.72-1.26 (2H, m). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.03 min. LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.80 min, 383 (M+1)⁺.

15 Example 62**4-[2-(N-(1-Carboxy-2-hydroxy)ethyl)carboxamido-pyrrolidin-1-oyl]phenyl 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.15 (2H, d); 7.64 (2H, d); 7.57 (2H, d); 7.24 (2H, d); 4.60 (1H, m); 4.48 (1H, m); 4.17 (2H, s); 3.90-3.20 (4H, m); 2.28 (1H, m); 2.10-1.60 (3H, m), Hplc (Magellan C8, Gradient 4, water/acetonitrile/TFA) rt 8.17min, LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.35min, 456 (M+1)⁺.

Example 63**4-[(4-Ethoxycarbonylmethyl)piperazin-1-oylphenyl] 4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.31 (2H, d); 7.83 (2H, d); 7.79 (2H, d); 7.57 (2H, d); 4.50 (2H, q); 4.42 (2H, s); 4.30 (2H, s); 4.10 (4H, bs); 3.58 (4H, bs); 1.50 (3H, t). Hplc (magellan C8, Gradient 5, water/acetonitrile/TFA) rt 7.37min. LC-MS (magellan C18, Gradient 5, water/acetonitrile/TFA) rt 1.40min, 426 (M+1)⁺.

Example 64

- 37 -

**4-[4-(Phenylsulfonylcarboxamido)piperidin-1-oyl]phenyl
4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.30 (2H, d); 8.05 (2H, d); 7.76-
7.60 (5H, m); 7.54 (2H, d); 7.39 (2H, d), 4.60-4.49 (1H,
5 m); 4.29 (2H, s); 3.87-3.74 (1H, m), 3.26-2.95 (2H, m);
2.64-2.53 (1H, m); 1.95-1.70 (2H, m); 1.68-1.53 (2H, m).
Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA)
rt 9.17 min. LC-MS (Magellan C18, Gradient 6,
water/acetonitrile/TFA) rt 2.29 min, 522 (M+1)⁺.

10

Example 65

**4-Carboxyphenyl 4-(aminomethyl)benzoate trifluoroacetate
salt**

¹H nmr (d₄ methanol) 8.28 (2H, d); 8.14 (2H, d); 7.69
15 (2H, d); 7.38 (2H, d); 4.27 (2H, s). Hplc (Magellan C8,
Gradient 5, Water/acetonitrile/TFA) rt 7.81 min. LC-MS
(Magellan C18, Gradient 6, water/acetonitrile/TFA) rt
2.27 min, 272 (M+1)⁺.

20

Example 66

**2-(2-Carboxypyrrolidin-1-oyl)phenyl 4-
(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.25 (2H, d); 7.70-7.30 (6H, m);
4.40 (1H, m); 4.25 (2H, s); 3.50 (2H, m); 2.40-1.80 (4H,
25 m), Hplc (Magellan C8, Gradient 4,
water/acetonitrile/TFA) rt 8.76min, LC-MS (Magellan C18,
Gradient 6, water/acetonitrile/TFA) rt 1.83min, 369
(M+1)⁺.

30

Example 67

**3-(2-Carboxypyrrolidin-1-oyl)phenyl 4-
(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.40 (2H, d); 7.80 (2H, d); 7.70-7.40
(4H, m); 4.80-4.50 (1H, m); 4.39 (2H, s); 3.80 (2H, m);
35 2.50 (1H, m); 2.15 (3H, m), Hplc (Magellan C8, Gradient
4, water/acetonitrile/TFA) rt 7.68min, LC-MS (Magellan
C18, Gradient 6, water/acetonitrile/TFA) rt 1.93min, 369

(M+1)⁺.

Example 68

4-(N-Phenylsulfonylcarboxamido)phenyl 4-

5 **(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.27 (2H, d); 8.12 (2H, d); 8.00 (2H, d); 7.71-7.58 (5H, m); 7.37 (2H, d); 4.29 (2H, s).

Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA)

rt 9.74 min. LC-MS (Magellan C18, Gradient 6,

10 water/acetonitrile/TFA) rt 2.61 min, 411 (M+1)⁺.

Example 69

4-(Tetrazolylmethyl)phenyl 4-(aminomethyl)benzoate

trifluoroacetate salt

15 ¹H nmr (d₄ methanol) 8.27 (2H, d); 7.68 (2H, d); 7.49 (2H, d); 7.30 (2H, d); 4.27 (2H, s); 3.97 (2H, s) M.S.TOF 310 (M+1)⁺, Hplc (Magellan C8, Gradient 4, water/acetonitrile/TFA) rt 10.15min, Hplc (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 2.12min.

20

Example 70

4-(N-Methanesulfonylcarboxamido)phenyl 4-

(aminomethyl)benzoate trifluoroacetate salt

25 ¹H nmr (d₄ methanol) 8.25 (2H, d); 8.01 (2H, d); 7.68 (2H, d); 7.43 (2H, d); 4.28 (2H, s); 3.39 (3H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 7.68 min. LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.74 min, 349 (M+1)⁺.

30 **Example 71**

4-[(2-Amino-2-carboxy)ethyl]phenyl 4-

(aminomethyl)benzoate ditrifluoroacetate salt

¹H nmr (d₄ methanol) 8.28 (2H, d); 7.70 (2H, d); 7.46 (2H, d); 7.29 (2H, d); 4.29 (2H, s); 4.19 (1H, dd); 3.41 (1H, dd); 3.20 (1H, dd). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 6.77 min. LC-MS (Magellan C18, Gradient 6, water/acetonitrile/TFA) rt 1.35 min,

35

315 (M+1)⁺.

Example 72

[4-(4-Carboxypiperidin-1-oyl)-2-nitro]phenyl 4-
5 (aminomethyl)benzoate trifluoroacetate salt
¹H nmr (d₄ methanol) 8.33-8.28 (3H, m); 7.91 (1H, dd);
7.73 (2H, d); 7.66 (1H, d); 4.57-4.38 (1H, m); 4.31 (2H,
s); 3.83-3.70 (1H, m), 3.36-3.13 (2H, m); 2.78-2.66 (1H,
m); 2.17-1.92 (2H, m); 1.87-1.69 (2H, m). Hplc
10 (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt
8.49 min. LC-MS (Magellan C18, Gradient 6,
water/acetonitrile/TFA) rt 1.83 min, 428 (M+1)⁺.

Example 73

15 [2-(4-Carboxypiperidin-1-oyl)-4-nitro]phenyl 4-
(aminomethyl)benzoate trifluoroacetate salt
¹H nmr (d₄ methanol) 8.48 (1H, dd); 8.39 (1H, br s); 8.26
(2H, d); 7.77-7.67 (3H, m); 4.51-4.36 (1H, m); 4.30 (2H,
s); 3.68-3.59 (1H, m), 3.31-3.18 (1H, m); 3.02 (1H, td);
20 2.68-2.58 (1H, m); 2.00-1.90 (2H, m); 1.78-1.30 (2H, m).
Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA)
rt 9.18 min. LC-MS (Magellan C18, Gradient 6,
water/acetonitrile/TFA) rt 2.07 min, 428 (M+1)⁺.

25 **Example 74**

4-Sulphonamidophenyl-4-(aminomethyl)benzoate
trifluoroacetate salt
¹H nmr (d₄ methanol) 8.28 (2H, d); 8.02 (2H, d); 7.68
(2H, d); 7.46 (2H, d); 4.27 (2H, s). Hplc (Magellan C8,
30 Gradient 5, Water/acetonitrile/TFA) rt 8.70 min. LC/MS
(Magellan C18 Gradient 6, water/acetonitrile/TFA) rt
1.17 min, 307 (M+1)⁺.

Example 75

35 (4-Carboxymethyl-2-nitro)phenyl-4-(aminomethyl)benzoate
trifluoroacetate salt
¹H nmr (d₄ methanol) ¹H nmr (d₄ methanol) 8.29 (2H, d);

- 40 -

8.18 (1H, d); 7.78 (1H, dd); 7.71 (2H, d); 7.49 (1H, d);
4.30 (2H, s); 3.85 (2H, s). Hplc (Magellan C8, Gradient
5, Water/acetonitrile/TFA) rt 9.25 min. LC/MS (Magellan
C18 Gradient 6, water/acetonitrile/TFA) rt 1.25 min, 331
5 (M+1)⁺.

Example 76

**4-[2-[(Pyrrolidin-2-oyl)amino-2-carboxy]ethyl]phenyl-4-
(aminomethyl)benzoate trifluoroacetate salt**

10 ¹H nmr (d₄ methanol) 8.25 (2H, d); 7.67 (2H, d); 7.38
(2H, d); 7.19 (2H, d); 4.87-4.72 (2H, m); 4.27-4.21 (3H,
m); 3.46-3.31 (2H, m); 3.07 (1H, dd); 2.50-2.35 (1H, m);
2.16-1.97 (3H, m). Hplc (Magellan C8, Gradient 5,
Water/acetonitrile/TFA) rt 7.88 min. LC/MS (Magellan C18
15 Gradient 6, water/acetonitrile/TFA) rt 1.00 min, 412
(M+1)⁺.

Example 77

**4-[(4-Carboxypiperidin-1-oyl)methyl]phenyl-4-
(aminomethyl)benzoate trifluoroacetate salt**

20 ¹H nmr (d₄ methanol) 8.27 (2H, d); 7.68 (2H, d); 7.38
(2H, d); 7.24 (2H, d); 4.40 (1H, d); 4.27 (2H, s); 4.01
(1H, d); 3.86 (2H, s); 3.23 (1H, t); 2.93 (1H, t); 2.67-
2.54 (1H, m); 2.00-1.87 (2H, m); 1.65-1.45 (2H, m).
25 Hplc (Symmetry Rp8, Gradient 8, Water/acetonitrile/TFA)
rt 5.04 min. LC/MS (Magellan C18 Gradient 6,
water/acetonitrile/TFA) rt 1.32 min, 397 (M+1)⁺.

Example 78

**[(4-Carboxymethylpiperazin-1-oyl)methyl]phenyl-4-
(aminomethyl)benzoate ditrifluoroacetate salt**

30 ¹H nmr (d₄ methanol) 8.25 (2H, d); 7.67 (2H, d); 7.37
(2H, d); 7.23 (2H, d); 4.26 (2H, s); 4.13 (2H, s); 4.03-
3.86 (6H, m); 3.47-3.34 (4H, m). Hplc (Symmetry Rp8,
35 Gradient 8, Water/acetonitrile/TFA) rt 3.90 min. LC/MS
(Magellan C18 Gradient 6, water/acetonitrile/TFA) rt
1.07 min, 412 (M+1)⁺.

Example 79

4-[(N-Carboxymethyl)acetamido]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

5 ¹H nmr (d₄ methanol) 8.27 (2H, d); 7.66 (2H, d); 7.44 (2H, d); 7.21 (2H, d); 4.26 (2H, s); 3.95 (2H, s); 3.6 (2H, s). Hplc (Symmetry Rp8, Gradient 8, Water/acetonitrile/TFA) rt 4.42 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.17 min, 343 (M+1)⁺.

10

Example 80

4-[(2-Carboxypyrrolidin-1-oyl)methyl]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

15 ¹H nmr (d₄ methanol) 8.26 (2H, d); 7.66 (2H, d); 7.40 (2H, d); 7.21 (2H, d); 4.48 (1H, dd); 4.26 (2H, s); 3.82 (2H, s); 3.73-3.59 (2H, m); 2.35-1.98 (4H, m). Hplc (Symmetry Rp8, Gradient 8, Water/acetonitrile/TFA) rt 4.97 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.35 min, 383 (M+1)⁺.

20

Example 81

4-[4-(Carboxymethyl)piperazin-1-oyl]phenyl-4-(aminomethyl)benzoate ditrifluoroacetate salt

25 ¹H nmr (d₄ methanol) 8.28 (2H, d); 7.69 (2H, d); 7.64 (2H, d); 7.42 (2H, d); 4.27 (2H, s); 4.19 (2H, s); 4.08-3.90 (4H, m); 3.56-3.44 (4H, m). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 9.74 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 0.80 min, 398 (M+1)⁺.

30

Example 82

4-(Carboxymethyl-aminosulphonyl)phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

35 ¹H nmr (d₄ methanol) 8.30 (2H, d); 8.01 (2H, d); 7.71 (2H, d); 7.50 (2H, d); 4.31 (2H, s); 3.79 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt

- 42 -

9.04 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.20 min, 365 (M+1)⁺.

Example 83

- 5 4-(N-Benzoylamino-sulphonyl)phenyl-4-(aminomethyl)benzoate trifluoroacetate salt
 ¹H nmr (d₄ methanol) 8.33 (2H, d); 8.27 (2H, d); 7.89 (2H, d); 7.73-7.62 (3H, m); 7.59-7.50 (4H, m); 4.30 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 13.76 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.83 min, 411 (M+1)⁺.

Example 84

- 15 4-[4-(Aminomethyl)benzoylamino-sulphonyl]phenyl-4-(aminomethyl)benzoate ditrifluoroacetate salt
 ¹H nmr (d₄ methanol) 8.29 (2H, d); 8.21 (2H, d); 7.96 (2H, d); 7.70 (2H, d); 7.58 (2H, d); 7.52 (2H, d); 4.29 (2H, s); 4.22 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 10.44 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.12 min, 440 (M+1)⁺.

Example 85

- 25 4-(Tetrazol-5-yl)phenyl-4-(aminomethyl)benzoate trifluoroacetate salt
 ¹H nmr (d₄ methanol) 8.24 (2H, d); 8.08 (2H, d); 7.61 (2H, d); 7.32 (2H, d); 4.21 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 9.81 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.17 min, 296 (M+1)⁺.

Example 86

- 35 4-[N-(Tetrazol-5-ylmethyl)carboxamido]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt
 ¹H nmr (d₄ methanol) 8.31 (2H, d); 8.06 (2H, d); 7.70 (2H, d); 7.43 (2H, d); 4.98 (2H, s), 4.30 (2H, s). Hplc

- 43 -

(Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.84 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.05 min, 353 (M+1)⁺.

5 **Example 87**

3-[(2-Carboxy-2-acetylamino)ethyl]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.29 (2H, d); 7.69 (2H, d); 7.43 (1H, t); 7.24 (1H, d); 7.17-7.11 (2H, m); 4.73 (1H, dd);
10 4.29 (2H, s); 3.31 (1H, dd); 3.04 (1H, dd); 1.96 (3H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.75 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.13 min, 357 (M+1)⁺.

15

Example 88

2[(2-Carboxy-2-acetylamino)ethyl]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.34 (2H, d); 7.68 (2H, d); 7.40-
20 7.34 (2H, m); 7.30-7.20 (2H, m); 4.77 (1H, dd); 4.27 (2H, s); 3.25 (1H, dd); 2.90 (1H, dd); 1.88 (3H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 9.26 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.27 min, 357 (M+1)⁺.

25

Example 89

2-[(Carboxymethyl)acetamido]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.30 (2H, d); 7.68 (2H, d); 7.51-
30 7.39 (2H, m); 7.36-7.26 (2H, m); 4.27 (2H, s); 3.82 (2H, s); 3.65 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.42 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.20 min, 343 (M+1)⁺.

35

Example 90

2-[[[(1-Carboxy-2-hydroxy)ethyl]acetamido]phenyl-4-

(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.32 (2H, d); 7.68 (2H, d); 7.52-7.39 (2H, m); 7.37-7.26 (2H, m); 4.43 (1H, t); 4.28 (2H, s); 3.86 (1H, dd); 3.74 (1H, dd); 3.68 (2H, s). Hplc
5 (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.69 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.15 min, 373 (M+1)⁺.

Example 91

10 **2-[(alpha-Carboxy)benzylacetamidol]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.25 (2H, d); 7.62 (2H, d); 7.48-7.26 (9H, m); 5.33 (1H, s); 4.27 (2H, s); 3.67 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA)
15 rt 10.11 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.53 min, 419 (M+1)⁺.

Example 92

20 **2-(Carboxymethylamido)phenyl-4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.30 (2H, d); 7.78 (1H, d); 7.71-7.62 (3H, m); 7.46 (1H, t); 7.37 (1H, d); 4.28 (2H, s); 4.00 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 7.93 min. LC/MS (Magellan C18
25 Gradient 6, water/acetonitrile/TFA) rt 1.25 min, 329 (M+1)⁺.

Example 93

30 **2-[(1-Carboxy-2-hydroxy)ethylamidol]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt**

¹H nmr (d₄ methanol) 8.29 (2H, d); 7.83 (1H, d); 7.67-7.61 (3H, m); 7.46 (1H, t); 7.36 (1H, d); 4.58 (1H, t); 4.27 (2H, s); 3.92 (1H, dd); 3.83 (1H, dd). Hplc
(Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.44 min. LC/MS (Magellan C18 Gradient 6,
35 water/acetonitrile/TFA) rt 1.03 min, 359 (M+1)⁺.

Example 94

2-[(1-Carboxy-2-phenyl)ethylamidolphenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.19 (2H, d); 7.66-7.57 (4H, m);
5 7.44-7.30 (2H, m); 7.28-7.17 (5H, m); 4.78 (1H, dd);
4.28 (2H, s); 3.27 (1H, dd); 3.04 (1H, dd). Hplc
(Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt
9.70 min. LC/MS (Magellan C18 Gradient 6,
water/acetonitrile/TFA) rt 1.72 min, 419 (M+1)⁺.

10

Example 95

2-[N-(1(R)-Carboxy-5-aminopenyl)carboxamidolphenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.29 (2H, d); 7.78 (1H, d); 7.71-
15 7.62 (3H, m); 7.47 (1H, t); 7.36 (1H, d); 4.51 (1H, dd);
4.29 (2H, s); 2.92-2.83 (2H, m); 2.00-1.85 (1H, m);
1.85-1.56 (3H, m); 1.56-1.39 (2H, m). Hplc (Symmetry
Rp8, Gradient 7, Water/acetonitrile/TFA) rt 5.65 min.
LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA)
20 rt 1.05 min, 400 (M+1)⁺.

Example 96

2-[N-(1(S)-Carboxy-5-aminopenyl)carboxamidolphenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.28 (2H, d); 7.80-7.73 (1H, m);
25 7.73-7.59 (3H, m); 7.46 (1H, t); 7.35 (1H, d); 4.51 (1H,
dd); 4.29 (2H, s); 2.90-2.79 (2H, m); 2.00-1.86 (1H, m);
1.86-1.57 (3H, m); 1.53-1.39 (2H, m). Hplc (Symmetry
Rp8, Gradient 7, Water/acetonitrile/TFA) rt 4.37 min.
30 LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA)
rt 1.08 min, 400 (M+1)⁺.

Example 97

[4-Chloro-2-(carboxymethyl)amidolphenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.28 (2H, d); 7.79 (1H, d); 7.69-
35 7.62 (3H, m); 7.39 (1H, d); 4.28 (2H, s); 3.99 (2H, s).

- 46 -

Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA)
rt 9.45 min. LC/MS (Magellan C18 Gradient 6,
water/acetonitrile/TFA) rt 1.28 min, 363 (M+1)⁺.

5 **Example 98**

[4-Chloro-2-(1-carboxy-2-hydroxy)ethylamido]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.29 (2H, d); 7.84 (1H, d); 7.68-7.61 (3H, m); 7.39 (1H, d); 4.57 (1H, t); 4.27 (2H, s);
10 3.92 (1H, dd); 3.84 (1H, dd). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 8.85 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.30 min, 393 (M+1)⁺.

15 **Example 99**

[4-Chloro-2-[(1-carboxy-2-phenyl)ethylamido]]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.14 (2H, d); 7.63-7.51 (4H, m); 7.32 (1H, d); 7.26-7.15 (5H, m); 4.73 (1H, dd); 4.25
20 (2H, s); 3.25 (1H, dd); 3.00 (1H, dd). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 10.59 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 2.75 min, 453 (M+1)⁺.

25 **Example 100**

[4-Chloro-2-[(alpha-carboxy)benzylamido]]phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

¹H nmr (d₄ methanol) 8.18 (2H, d); 7.77 (1H, d); 7.66-7.60 (3H, m); 7.39-7.29 (6H, d); 5.52 (1H, s); 4.29 (2H,
30 s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 10.45 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.77 min, 439 (M+1)⁺.

35 **Example 101**

2-(Tetrazol-5-yl)phenyl-4-(aminomethyl)benzoate trifluoroacetate salt

- 47 -

¹H nmr (d₄ methanol) 8.27 (2H, d); 8.00 (1H, d); 7.75 (1H, t); 7.67 (2H, d); 7.62-7.50 (2H, m); 4.29 (2H, s). Hplc (Magellan C8, Gradient 5, Water/acetonitrile/TFA) rt 10.26 min. LC/MS (Magellan C18 Gradient 6, water/acetonitrile/TFA) rt 1.37 min, 296 (M+1)⁺.

Example 102**Phenyl 4-(aminomethyl)-2-methylbenzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.25 (1H, d); 7.54-7.47 (4H, m); 7.38-7.32 (1H, m); 7.30-7.25 (2H, m); 4.24 (2H, s); 2.74 (3H, s). M.S. TOF 242 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, Water/acetonitrile/TFA) rt 9.69 min. Hplc (SymmetryC8 Gradient 2, Water/acetonitrile/TFA) rt 9.91 min.

Example 103**Phenyl 4-(aminomethyl)-3-methylbenzoate hydrochloride salt**

¹H nmr (d₄ methanol) 8.17-7.75 (2H, m); 7.62 (1H, d); 7.51 (2H, t); 7.35 (1H, t); 7.27 (2H, d); 4.32 (2H, s); 2.57 (3H, s). M.S. TOF 242 (M+1)⁺. Hplc (Jupiter5 C18, Gradient 1, Water/acetonitrile/TFA) rt 9.40 min. Hplc (SymmetryC8 Gradient 2, Water/acetonitrile/TFA) rt 9.82 min.

References

1. Still, W.C.; Kahn, M.; Mitra, A. *J.Org.Chem* 1978, 43, 2923
2. Smith, J., Liras, J.L., Schneider, S.E., Anslyn, E.V. *J Org Chem* 1996, 61, 8811

Protocol for Tryptase Inhibition Assay

Tryptase assays were carried out at room temperature in 0.1 M phosphate buffer, 0.5 mg/ml heparin, pH 7.4 according to a method of Tapparelli et

- 48 -

al. (1993) *J. Biol. Chem.* 268, 4734-4741. Purified human lung tryptase was purchased from Dr Andrew Walls, Immunopharmacology Group, Southampton General Hospital, Southampton, UK. The chromogenic substrate for tryptase, S-2366, was purchased from Quadratech, Epsom, Surrey, UK. Product (p-nitroaniline) was quantified by absorption at 405nm in 96 well microplates using a Dynatech MR 5000 reader (Dynex Ltd, Billingshurst, UK). K_m and K_i were calculated using SAS software. A K_m value of 216 μ M was determined for tryptase/S-2366. Inhibitor stock solutions were prepared at 40 mM in Me₂SO and tested within the range 100mM-1nM. Accuracy of K_i measurements was confirmed by comparison with K_i values of a known inhibitor of tryptase. In agreement with published data, benzamidine inhibited tryptase with a K_i value of 30 μ M.

The tryptase pK_i's of a number of the compounds of the invention are illustrated in Table 1 below. Also quoted are the trypsin pK_i's of the compounds.

Table 1

Ex. No.	Ar	pK _i tryptase	pK _i trypsin
10	4-Cyanophenyl	9.22	7.99
16	6-quinolyl	8.33	7.48
24	6'-carboxymethyl-2-naphthyl	8.17	7.42

In all cases R and Y represent hydrogen in formula (I).

These results clearly illustrate the efficacy of the compounds of the invention as well as their selectivity for tryptase over the serine protease trypsin.

Protocol for assessment of plasma stability.

The stability of compounds on incubation in human plasma

- 49 -

can be used to demonstrate the hydrolytic stability of the ester moiety towards the range of esterases and proteases normally present in plasma. As such, this assay is an informative measure of metabolic stability in the whole animal for compounds where ester hydrolysis is a major metabolic pathway.

In general, 10 uM samples of compound were incubated at 37 C in 3 ml human plasma. Aliquots were removed at intervals over a 4 hour incubation, extracted by solid phase techniques and analysed by HPLC.

The half-life of hydrolysis of some representative esters are illustrated in Table 2 below.

Table 2


Ex. No.	Ar	t1/2 of hydrolysis on plasma incubation
10	4-cyanophenyl	< 5 minutes
57	4-[4-Carboxy piperidin-1-oyl] phenyl	107 min
52	4-[(2-Acetylamino-2-carboxy)ethyl] phenyl	22 hours

In all cases R and Y represent hydrogen in formula (I).

These results indicate that the stability to hydrolysis by plasma enzymes is greatly enhanced for some compounds, which may therefore be preferred for therapeutic application, particularly for systemic administration.

Claims

1. Use of a tryptase inhibitor of formula I



10 wherein R represents hydrogen, alkyl, alkenyl, hydroxy, alkoxy, aminoalkyl, hydroxyalkyl, carboxyalkyl, alkoxyalkyl, amino, halo, cyano, nitro, thiol, alkylthio, haloalkoxy or haloalkyl;

15 Ar represents an optionally substituted carbocyclic or heterocyclic aryl group with the proviso that when Ar represents a naphthyl moiety it is not substituted by amidino or guanidine; and

20 Y represents a hydrogen atom or alkyl group; or a physiologically tolerable salt thereof; in the manufacture of a medicament for use in a method of treatment of the human or non-human animal body to combat a condition responsive to said inhibitor.

25 2. Use as claimed in claim 1 wherein Y represents hydrogen.

3. Use as claimed in either one of claims 1 or 2 wherein R represents hydrogen.

30 4. Use as claimed in any one of claims 1 to 3 wherein Ar represents optionally substituted phenyl, naphthyl, pyridyl, quinolyl or isoquinolyl.

35 5. Use as claimed in claim 4 wherein Ar represents a phenyl or naphthyl group substituted by one or more substituents selected from: halo, methylenedioxy, -R¹,

- 51 -

$-\text{NR}^1\text{COR}^2$, C_{2-6} -alkenyl, $-(\text{CH}_2)_w\text{-OR}^1$, $-(\text{C}_{1-6})$ -perfluoroalkyl,
 $-(\text{CH}_2)_w\text{CN}$, $-(\text{CH}_2)_w\text{NO}_2$, $-(\text{CH}_2)_w\text{CF}_3$, $-(\text{CH}_2)_w\text{S(O)}_r\text{R}^1$,
 $-(\text{CH}_2)_w\text{NR}^1\text{R}^2$, $-(\text{CH}_2)_w\text{COR}^1$, $-(\text{CH}_2)_w\text{CO}_2\text{R}^1$, $-(\text{CH}_2)_w\text{CONR}^1\text{R}^2$,
 $-(\text{CH}_2)_w\text{SO}_2\text{NR}^1\text{R}^2$, $-(\text{CH}_2)_w\text{NHCO}_2\text{R}^1$, $-(\text{CH}_2)_w\text{NHCOR}^1$, $-(\text{CH}_2)_w\text{NHCO}_2\text{R}^1$,
5 $-\text{OC(=O)R}^1$, $-(\text{CH}_2)_w\text{-CH(NHCOR}^1\text{)-COOR}^2$, $-(\text{CH}_2)_w\text{-CH(NR}^1\text{R}^2\text{)-COOR}^1$,
 $-(\text{CH}_2)_w\text{-CONH-SO}_2\text{-R}^1$, $-(\text{CH}_2)_w\text{-SO}_2\text{-NHCO-R}^1$, $-(\text{CH}_2)_w$ -
tetrazole, $-(\text{CH}_2)_w\text{-P(O)}_{2-3}\text{-R}^1$, $-(\text{CH}_2)_w\text{-C(=O)-R}^3$ and
optionally substituted aryl where R^1 and R^2 independently
represent H, C_{1-8} alkyl, C_{3-7} cycloalkyl, or $-(\text{CH}_2)_w\text{-Ph}$, or
10 R^1 and R^2 are optionally connected by a bond to form a 5-
8 atom cyclic structure or connected via an O, S or N
atom to form a 5-8 atom heterocyclic structure and where
 R^1 and/or R^2 are also optionally substituted with $-(\text{CH}_2)_w$ -
 COOR^1 , $-(\text{CH}_2)_w\text{-CH(NHCOR}^1\text{)-COOR}^2$, $-(\text{CH}_2)_w\text{-CH(NR}^1\text{R}^2\text{)-COOR}^1$,
15 $-(\text{CH}_2)_w\text{-CONH-SO}_2\text{-R}^1$, $-(\text{CH}_2)_w\text{-SO}_2\text{-NHCO-R}^1$, $-(\text{CH}_2)_w$ -tetrazole,
 $-(\text{CH}_2)_w\text{-S(O)}_r\text{-R}^1$, or $-(\text{CH}_2)_w\text{-P(O)}_{2-3}\text{-R}^1$; R^3 is an oligomer
comprising 1-4 aminoacid monomers, terminated by a free
carboxylic acid, ester or amide functionality; and $w=0-5$
and $r=0-2$.

20

6. Use as claimed in claim 5 wherein Ar is substituted by an electron-withdrawing group and/or a protected or unprotected acidic group.

25

7. Use as claimed in claim 6 wherein said electron withdrawing group is selected from cyano, nitro, carboxamido, alkylsulfenyl, alkylsulfonyl, alkylaminosulfonyl, trifluoromethyl or halogen.

30

8. Use as claimed in claim 6 or 7 wherein said acidic group is selected from alkyl or aryl carboxylic acids and esters, acyl sulphonamide, sulphonylamidocarboxyalkyl, carboxyamidosulphonylalkyl, tetrazole, sulphonic acid or phosphonic acid each bonded
35 to the Ar ring directly or via an alkyl, sulphonamidoalkyl or carboxamidoalkyl linkage, the linkage itself being optionally substituted by C_{1-4}

- 52 -


alkyl, CN, NO₂, NH₂, NHCO-alkyl, or halogen.

9. Use as claimed in claim 8 wherein if Ar is a phenyl derivative then said acidic substituent is present on the para position of the phenyl ring.

10. Use as claimed in claim 8 wherein if Ar is phenyl said acidic substituent is present on the ortho position and said electron withdrawing substituent is present on the para position of the phenyl ring.

11. A compound of formula (II)

15



20 wherein R represents hydrogen, alkyl, alkenyl, hydroxy, alkoxy, aminoalkyl, hydroxyalkyl, carboxyalkyl, alkoxyalkyl, amino, halo, cyano, nitro, thiol, alkylthio, haloalkoxy or haloalkyl;

Y represents a hydrogen atom or alkyl group;; and

25 Z represents a phenyl group substituted by methylenedioxy, -NR¹COR², C₂₋₆-alkenyl, -(CH₂)_w-OR¹, -(C₁₋₆)-perfluoroalkyl, -(CH₂)_wCN, -(CH₂)_wNO₂, -(CH₂)_wCF₃, -(CH₂)_wS(O)₂R¹, -(CH₂)_wNR¹R², -(CH₂)_wCOR¹, -(CH₂)_wCONR¹R², -(CH₂)_wSO₂NR¹R², -(CH₂)_wNHSO₂R¹, -(CH₂)_wNHCOR¹, -(CH₂)_wNHCO₂R¹, -OC(=O)R¹, -(CH₂)_w-CH(NHCOR¹)-COOR², -(CH₂)_w-CH(NR¹R²)-COOR¹, -(CH₂)_w-CONH-SO₂-R¹, -(CH₂)_w-SO₂-NHCO-R¹, -(CH₂)_w-tetrazole, -(CH₂)_w-P(O)₂₋₃-R¹, -(CH₂)_w-C(=O)-R³ and optionally substituted aryl where R¹ and R² independently represent H, C₁₋₈ alkyl, C₃₋₇ cycloalkyl, or -(CH₂)_w-Ph, or R¹ and R² are optionally connected by a bond to form a 5-8 atom cyclic structure (eg. piperidine) or connected via an O, S or N atom to form a 5-8 atom heterocyclic

- 53 -

structure (eg. morpholine, piperazine) and where R^1 and/or R^2 are also optionally substituted with $-(CH_2)_w-$ COOR¹, $-(CH_2)_w-$ CH(NHCOR¹)-COOR², $-(CH_2)_w-$ CH(NR¹R²)-COOR¹, $-(CH_2)_w-$ CONH-SO₂-R¹, $-(CH_2)_w-$ SO₂-NHCO-R¹, $-(CH_2)_w-$ tetrazole,
 5 $-(CH_2)_w-$ S(O)_r-R¹, or $-(CH_2)_w-$ P(O)₂₋₃-R¹; where R³ is an oligomer comprising 1-4 aminoacid monomers, such as the natural aminoacids glycine, proline and serine, terminated by a free carboxylic acid, ester or amide functionality; and w=0-5 and r=0-2; or

10 Z represents a phenyl group substituted in the 2-position by nitro or in the 3-position by methoxy; or

Z represents a naphthyl group substituted by halo, methylenedioxy, -R¹, -NR¹COR², C₂₋₆-alkenyl, $-(CH_2)_w-$ OR¹, $-(C_{1-6})-$ perfluoroalkyl, $-(CH_2)_w$ CN, $-(CH_2)_w$ NO₂, $-(CH_2)_w$ CF₃,
 15 $-(CH_2)_w$ S(O)_rR¹, $-(CH_2)_w$ NR¹R², $-(CH_2)_w$ COR¹, $-(CH_2)_w$ CO₂R¹, $-(CH_2)_w$ CONR¹R², $-(CH_2)_w$ SO₂NR¹R², $-(CH_2)_w$ NHSO₂R¹, $-(CH_2)_w$ NHCOR¹, $-(CH_2)_w$ NHCO₂R¹, $-OC(=O)R^1$, $-(CH_2)_w-$ CH(NHCOR¹)-COOR², $-(CH_2)_w-$ CH(NR¹R²)-COOR¹, $-(CH_2)_w-$ CONH-SO₂-R¹, $-(CH_2)_w-$ SO₂-NHCO-R¹, $-(CH_2)_w-$ tetrazole, $-(CH_2)_w-$ P(O)₂₋₃-R¹, $-(CH_2)_w-$ C(=O)-R³ and
 20 optionally substituted aryl where R¹ and R² independently represent H, C₁₋₈ alkyl, C₃₋₇ cycloalkyl, or $-(CH_2)_w-$ Ph, or R¹ and R² are optionally connected by a bond to form a 5-8 atom cyclic structure or connected via an O, S or N atom to form a 5-8 atom heterocyclic structure and where
 25 R¹ and/or R² are also optionally substituted with $-(CH_2)_w-$ COOR¹, $-(CH_2)_w-$ CH(NHCOR¹)-COOR², $-(CH_2)_w-$ CH(NR¹R²)-COOR¹, $-(CH_2)_w-$ CONH-SO₂-R¹, $-(CH_2)_w-$ SO₂-NHCO-R¹, $-(CH_2)_w-$ tetrazole, $-(CH_2)_w-$ S(O)_r-R¹, or $-(CH_2)_w-$ P(O)₂₋₃-R¹; where R³ is an oligomer comprising 1-4 aminoacid monomers, terminated
 30 by a free carboxylic acid, ester or amide functionality; and w=0-5 and r=0-2; or

a heterocyclic aryl groups containing 5 to 10 ring atoms including 1, 2 or 3 ring heteroatoms selected from oxygen, nitrogen and sulphur; or

35 a physiologically tolerable salt thereof.

12. A compound of formula (II) as claimed in claim 11

for use in combatting a condition responsive to said inhibitor.

13. A pharmaceutical composition comprising a compound
5 of formula (II) as claimed in claim 11, together with at least one pharmaceutically acceptable excipient.

14. A pharmaceutical composition comprising a compound
10 of formula (I) as claimed in claims 1 to 10, together with one or more anti-asthma agents and at least one pharmaceutically acceptable excipient.

15. A method of treatment of human or non-human animal
15 body to combat a condition responsive to a tryptase inhibitor, said method comprising administering to said body an effective amount of a tryptase inhibitor as claimed in any one of claims 1 to 10.

INTERNATIONAL SEARCH REPORT

In tional Application No

PCT/GB 99/01263

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C229/38 A61K31/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARTIN POE ET AL.: "The enzymatic activity of human cytotoxic T-Lymphocyte Granzyme A and" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 284, no. 1, January 1991 (1991-01), pages 215-218, XP002110066 NEW YORK, US, US ISSN: 0003-9861 the whole document --- -/--	1-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 July 1999

Date of mailing of the international search report

06/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rufet, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01263

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TAKUO AOYAMA ET AL.: "Synthesis and structure-Activity study of protease inhibitors." CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 33, no. 4, 1985, pages 1458-1471, XP002110067 PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO., JP ISSN: 0009-2363 page 1460, paragraph 2; tables I-VI ---</p>	1-15
X	<p>THOMAS J. RYAN ET AL.: "Specificity of thrombin:..." BIOCHEMISTRY., vol. 15, no. 6, 1976, pages 1337-1341, XP002110068 AMERICAN CHEMICAL SOCIETY. EASTON, PA., US ISSN: 0006-2960 abstract; figure 1; table 1 ---</p>	1-15
X	<p>FR 2 500 826 A (TORII & CO LTD) 3 September 1982 (1982-09-03) cited in the application page 50; claim 1 ---</p>	11
X	<p>DE 19 51 061 A (DAIICHI SEIYAKU COMPANY LTD) 25 June 1970 (1970-06-25) cited in the application claims 1-11 ---</p>	11
X	<p>DE 19 66 174 A (DAIICHI SEIYAKU COMPANY LTD) 18 November 1971 (1971-11-18) cited in the application claims 1-10 ---</p>	11
X	<p>EP 0 048 433 A (TORII & CO LTD) 31 March 1982 (1982-03-31) cited in the application claims 1-4,9,13 ---</p>	11
X	<p>CHEMICAL ABSTRACTS, vol. 115, no. 16, 21 October 1991 (1991-10-21) Columbus, Ohio, US; abstract no. 166454u, JENSEN, EJVIND ET AL.: "Water-soluble aminoalkylbenzoates esters of phenols as prodrugs." page 473; column 1; XP002110069 abstract & ACTA PHARM. NORD., vol. 3, no. 1, 1991, pages 31-40, cited in the application ---</p>	11
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/01263

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 78, no. 3, 22 January 1973 (1973-01-22) Columbus, Ohio, US; abstract no. 15640t, page 350; column 2; XP002110070 abstract & JP 47 035902 A (DAIICHI SEIYAKU COMPANY LTD) 9 September 1972 (1972-09-09) ---	11
X	CHEMICAL ABSTRACTS, vol. 72, no. 15, 13 April 1970 (1970-04-13) Columbus, Ohio, US; abstract no. 78706r, page 364; column 2; XP002110071 abstract & JP 45 001252 A (DAIICHI SEIYAKU COMPANY LTD) 16 January 1970 (1970-01-16) ---	11
X	CHEMICAL ABSTRACTS, vol. 75, no. 20, 15 November 1971 (1971-11-15) Columbus, Ohio, US; abstract no. 121431y, page 219; column 2; XP002110072 abstract & JP 46 024257 A (DAIICHI SEIYAKU COMPANY LTD) 12 July 1971 (1971-07-12) ---	11
X	PATENT ABSTRACTS OF JAPAN vol. 006, no. 180 (C-125), 14 September 1982 (1982-09-14) & JP 57 095908 A (DAI ICHI SEIYAKU CO LTD), 15 June 1982 (1982-06-15) abstract -----	11

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/GB 99/01263

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2500826 A	03-09-1982	JP 1509450 C	26-07-1989
		JP 57142956 A	03-09-1982
		JP 63060738 B	25-11-1988
		JP 1585340 C	31-10-1990
		JP 2010822 B	09-03-1990
		JP 58049358 A	23-03-1983
		DE 3207023 A	30-09-1982
		GB 2096598 A,B	20-10-1982
		US 4490388 A	25-12-1984
DE 1951061 A	25-06-1970	AT 291976 B	15-07-1971
		BE 740202 A	13-04-1970
		CA 929942 A	10-07-1973
		CH 523222 A	31-05-1972
		CS 178061 B	31-08-1977
		DK 122954 B	01-05-1972
		FI 52076 B	28-02-1977
		FR 2020646 A	17-07-1970
		GB 1277227 A	07-06-1972
		IE 33596 B	21-08-1974
		NL 6915495 A,B	16-04-1970
		PH 9762 A	12-03-1976
		RO 57232 A	15-01-1975
		SE 365506 B	28-03-1974
		US 3699149 A	17-10-1972
		DE 1966174 A	18-11-1971
		RO 62462 A	15-10-1977
		ZA 6907042 A	30-06-1971
DE 1966174 A	18-11-1971	AT 291976 B	15-07-1971
		BE 740202 A	13-04-1970
		CA 929942 A	10-07-1973
		CH 523222 A	31-05-1972
		DE 1951061 A	25-06-1970
		DK 122954 B	01-05-1972
		FI 52076 B	28-02-1977
		FR 2020646 A	17-07-1970
		GB 1277227 A	07-06-1972
		IE 33596 B	21-08-1974
		NL 6915495 A,B	16-04-1970
		PH 9762 A	12-03-1976
		RO 57232 A	15-01-1975
		RO 62462 A	15-10-1977
		SE 365506 B	28-03-1974
		US 3699149 A	17-10-1972
		ZA 6907042 A	30-06-1971
EP 0048433 A	31-03-1982	JP 1655183 C	13-04-1992
		JP 3007663 B	04-02-1991
		JP 57179146 A	04-11-1982
		JP 1332984 C	28-08-1986
		JP 57053454 A	30-03-1982
		JP 61001063 B	13-01-1986
		AT 20051 T	15-06-1986
		AU 527371 B	03-03-1983
		AU 7506281 A	25-03-1982
		CA 1177488 A	06-11-1984
		CS 228534 B	14-05-1984

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/01263

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0048433 A		DD 201779 A DK 410681 A,B, FI 812876 A,B, GB 2083818 A,B PH 18109 A SU 1176832 A US 4454338 A US 4532255 A ZA 8106363 A	10-08-1983 17-03-1982 17-03-1982 31-03-1982 22-03-1985 30-08-1985 12-06-1984 30-07-1985 29-09-1982
JP 47035902 A		NONE	
JP 45001252 A		NONE	
JP 46024257 A		NONE	
JP 57095908 A	15-06-1982	NONE	